Eribulin-based antibody-drug conjugates and methods of use thereof

By using the antibody-drug conjugate compound Ab-(L-D)p combined with corticosteroids, the problem of high risk of ILD in anti-FRA ADC treatment was solved, and effective treatment and safety improvement of FRA-expressed cancers was achieved.

CN119013049APending Publication Date: 2024-11-22EISAI R&D MANAGEMENT CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202380033643.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-06-08
Filing Date
2023-04-11
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing anti-FRA ADC treatments have high side effects in subjects with FRA-expressed cancer, especially interstitial lung disease (ILD), and are difficult to effectively reduce.

Method used

Using the internalized anti-folate receptor alpha antibody or antigen binding fragment thereof by Mal-(PEG)2-Val-Cit-pAB from the antibody-drug conjugate compound Ab-(L-D)p, wherein Ab contains a specific amino acid sequence. The linker is attached to eriprin and administered at a dose of 8 mg to 50 mg/m² of body surface area in conjunction with the use of corticosteroids such as dexamethasone or prednisone to reduce the risk of ILD.

Benefits of technology

It significantly reduces the risk of ILD during anti-FRA ADC treatment, improves the safety and effectiveness of the treatment, and is suitable for a variety of types of FRA-expressed cancers, including ovarian cancer, breast cancer, and non-small cell lung cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005079127700000212
    Figure BDA0005079127700000212
  • Figure BDA0005079127700000221
    Figure BDA0005079127700000221
  • Figure BDA0005079127700000222
    Figure BDA0005079127700000222
Patent Text Reader

Abstract

Linker toxins and antibody-drug conjugates that bind to human oncological antigen targets such as folate receptor alpha and / or provide anti-tubulin drug activity are disclosed. These linker toxins and antibody-drug conjugates comprise an eribulin drug moiety and can be internalized into target antigen expressing cells. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering these antibody-drug conjugates provided herein.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Related Applications

[0002] This application claims the benefit of U.S. Provisional Application Serial No. 63 / 362,882, filed on April 12, 2022, and U.S. Provisional Application Serial No. 63 / 366,029, filed on June 8, 2022, which are incorporated herein by reference.

[0003] Background and Summary of the Invention

[0004] The present disclosure relates to methods for treating folate receptor alpha (FRA) expressing cancers using antibody drug conjugates (ADCs) that bind to folate receptor alpha and provide anti-tubulin drug activity. The present disclosure further relates to methods for reducing the risk of side effects (e.g., interstitial lung disease (ILD)) in treated subjects.

[0005] Cancer is one of the leading causes of morbidity and mortality worldwide, with approximately 14 million new cases and 8.2 million cancer-related deaths in 2012. The most common causes of cancer death are the following cancers: lung cancer (1.59 million deaths); liver cancer (745,000 deaths); stomach cancer (723,000 deaths); colorectal cancer (694,000 deaths); breast cancer (521,000 deaths); and esophageal cancer (400,000 deaths). The number of new cancer cases is expected to rise by approximately 70% over the next two decades to approximately 22 million new cancer cases per year (World Cancer Report 2014).

[0006] Microtubules are dynamic filamentous cytoskeleton proteins that participate in a variety of cellular functions, including intracellular migration and transport, cell signaling, and maintenance of cell shape. Microtubules also play a key role in mitotic cell division by forming the mitotic spindle required to separate chromosomes into two daughter cells. The biological functions of microtubules in all cells are largely regulated by their polymerization dynamics, which occurs through the reversible, non-covalent addition of α-tubulin dimers and β-tubulin dimers at both ends of the microtubules. This dynamic behavior and the resulting control of microtubule length are essential for the normal function of the mitotic spindle. Even a slight change in microtubule dynamics can involve the spindle checkpoint, blocking the cell cycle process during mitosis, and subsequently causing cell death (Mukhtar et al. (2014) Mol. Cancer Ther. [Molecular Cancer Therapy] 13: 275-84). Due to the rapid cell division of cancer cells, cancer cells are generally more sensitive to compounds that bind to tubulin and destroy their normal functions than normal cells. For this reason, tubulin inhibitors and other agents that target microtubules have emerged as a promising class of cancer therapeutics (Dumontet and Jordan (2010) Nat. Rev. Drug Discov. 9:790-803).

[0007] Folate receptor alpha (FRA) is a glycophosphatidylinositol (GPI)-linked membrane protein that binds folate. Although the role of FRA in normal and cancerous tissue biology is not fully understood, it is highly overexpressed in a high proportion of epithelial ovarian cancers (O'Shannessy et al. (2013) Int. J. Gynecol. Pathol. [International Journal of Gynecology] 32(3): 258-68) and in a certain proportion of non-small cell lung cancers (Christoph et al. (2014) Clin. Lung Cancer [Clinical Journal of Lung Cancer] 15(5): 320-30). FRA expression in normal tissues is also limited. These properties make FRA an attractive target for cancer immunotherapy.

[0008] The inventors have previously demonstrated that folate receptor alpha (FRA)-expressing cancers can be effectively treated using compounds having biological activity against FRA-expressing tumor cells, e.g., ADCs (e.g., anti-FRA ADCs, e.g., MORAb-202). However, there remains a need for more effective methods and dosing regimens for treating subjects with FRA-expressing cancers using anti-FRA ADCs (e.g., MORAb-202), e.g., to reduce the side effects of treatment.

[0009] The present disclosure provides improved methods and dosing regimens for treating folate receptor alpha (FRA) expressing cancers using anti-FRA ADCs (eg, MORAb-202).

[0010] In various embodiments, the disclosure relates to a method of treating a folate receptor alpha (FRA)-expressing cancer, the method comprising administering to a subject in need thereof an antibody-drug conjugate compound represented by formula (I):

[0011] Ab-(LD)p (I)

[0012] in

[0013] The Ab is an internalizing anti-folate receptor alpha antibody or internalizing antigen binding fragment thereof comprising: three heavy chain complementary determining regions (HCDRs) comprising the amino acid sequences of SEQ ID NO: 1 (HCDR1), SEQ ID NO: 2 (HCDR2), and SEQ ID NO: 3 (HCDR3); and three light chain complementary determining regions (LCDRs) comprising the amino acid sequences of SEQ ID NO: 4 (LCDR1), SEQ ID NO: 5 (LCDR2), and SEQ ID NO: 6 (LCDR3), as defined by the Kabat numbering system; or three heavy chain complementary determining regions (HCDRs) comprising the amino acid sequences of SEQ ID NO: 7 (HCDR1), SEQ ID NO: 8 (HCDR2), and SEQ ID NO: 9 (HCDR3); and three light chain complementary determining regions (LCDRs) comprising the amino acid sequences of SEQ ID NO: 10 (LCDR1), SEQ ID NO: 11 (LCDR2), and SEQ ID NO: 12 (LCDR3), as defined by the IMGT numbering system;

[0014] D is eribulin;

[0015] L is a cleavable linker comprising Mal-(PEG)2-Val-Cit-pAB; and

[0016] p is an integer from 1 to 8;

[0017] The antibody-drug conjugate is administered at a concentration of 8 mg to 50 mg of the antibody-drug conjugate per square meter (m 2 ) of the subject's body surface area (BSA) is administered to the subject.

[0018] In various embodiments, the disclosure relates to a method of reducing the risk of interstitial lung disease (ILD) in a subject being treated for a FRA-expressing cancer, the method comprising administering to the subject an antibody-drug conjugate having formula (I):

[0019] Ab-(LD)p (I)

[0020] in

[0021] The Ab is an internalizing anti-folate receptor alpha antibody or internalizing antigen binding fragment thereof comprising: three heavy chain complementary determining regions (HCDRs) comprising the amino acid sequences of SEQ ID NO: 1 (HCDR1), SEQ ID NO: 2 (HCDR2), and SEQ ID NO: 3 (HCDR3); and three light chain complementary determining regions (LCDRs) comprising the amino acid sequences of SEQ ID NO: 4 (LCDR1), SEQ ID NO: 5 (LCDR2), and SEQ ID NO: 6 (LCDR3), as defined by the Kabat numbering system; or three heavy chain complementary determining regions (HCDRs) comprising the amino acid sequences of SEQ ID NO: 7 (HCDR1), SEQ ID NO: 8 (HCDR2), and SEQ ID NO: 9 (HCDR3); and three light chain complementary determining regions (LCDRs) comprising the amino acid sequences of SEQ ID NO: 10 (LCDR1), SEQ ID NO: 11 (LCDR2), and SEQ ID NO: 12 (LCDR3), as defined by the IMGT numbering system;

[0022] D is eribulin;

[0023] L is a cleavable linker comprising Mal-(PEG)2-Val-Cit-pAB; and

[0024] p is an integer from 1 to 8;

[0025] The antibody-drug conjugate is administered at a concentration of 8 mg to 50 mg of the antibody-drug conjugate per square meter (m 2 ) of the subject's body surface area (BSA) is administered to the subject.

[0026] In some embodiments, the antibody or antigen-binding fragment comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 13 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 14. In some embodiments, the antibody or antigen-binding fragment comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 15 and a light chain comprising the amino acid sequence of SEQ ID NO: 16. In some embodiments, the antibody-drug conjugate is MORAb-202.

[0027] In some embodiments, p is an integer from 3 to 4.

[0028] In some embodiments, the dose of ADC is 8 mg to 44 mg / m 2In some embodiments, the dose of ADC is 11 mg to 44 mg / m 2 In some embodiments, the dose is 8 mg to 10 mg / m 2 In some embodiments, the dose is 33 mg / m 2 In some embodiments, the dose is 25 mg / m 2 In some embodiments, the dose is 17 mg / m 2 In some embodiments, the dose is 15 mg / m 2 In some embodiments, the dose is 10 mg / m 2 In some embodiments, the dose is 8 mg / m 2 The subject's BSA.

[0029] In some embodiments, the ADC is administered to a subject once every three weeks. In some embodiments, the ADC is administered to a subject once every two weeks. In some embodiments, the ADC is administered to a subject once a week.

[0030] In some embodiments, the subject has a weight value in the upper quartile of weight.

[0031] In some embodiments, the methods disclosed herein reduce the risk of ILD in a subject after administration of the ADC by at least 5%, at least 10%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, or at least 20%, compared to a treatment in which the ADC is administered at a weight-based dose (e.g., at a dose of 0.5 mg to 2 mg / kg of subject body weight (BW), e.g., at a dose of 0.9 mg to 1.2 mg / kg BW).

[0032] In some embodiments, the methods disclosed herein further include administering a corticosteroid. In some embodiments, the corticosteroid is administered prophylactically. In some embodiments, the corticosteroid is administered simultaneously or sequentially with the antibody-drug conjugate. In some embodiments, the corticosteroid is administered before or after the administration of the ADC. In some embodiments, the corticosteroid is dexamethasone. In some embodiments, dexamethasone is administered at a dose of 4 mg dexamethasone. In some embodiments, dexamethasone is administered at least once a day, or twice a day. In some embodiments, dexamethasone is administered for at least three days at the beginning of treatment with the ADC. In some embodiments, dexamethasone is administered orally. In some embodiments, the corticosteroid is prednisone. In some embodiments, prednisone is administered at a dose of at least 0.5 mg, at least 1 mg, or at least 2 mg prednisone. In some embodiments, prednisone is administered at a dose of 0.5 mg. In some embodiments, prednisone is administered at a dose of 1 mg. In some embodiments, prednisone is administered at a dose of 2 mg. In some embodiments, prednisone is administered at least once a day. In some embodiments, prednisone is administered for at least 14 days before the beginning of treatment with the ADC. In some embodiments, prednisone is administered orally. In some embodiments, the corticosteroid is methylprednisolone. In some embodiments, methylprednisolone is administered at a dose of 500 to 1000 mg methylprednisolone. In some embodiments, methylprednisolone is administered at least once a day. In some embodiments, prednisone is administered at least three days prior to the start of treatment with the ADC. In some embodiments, prednisone is administered intravenously.

[0033] In some embodiments, the ADC is administered intravenously.

[0034] In some embodiments, the folate receptor alpha expressing cancer treated by the methods disclosed herein is ovarian cancer, breast cancer, non-small cell lung cancer, or endometrial cancer. In some embodiments, ovarian cancer is platinum-resistant ovarian cancer. In some embodiments, breast cancer is triple-negative breast cancer. In some embodiments, non-small cell lung cancer is metastatic non-small cell lung cancer.

[0035] In some embodiments, the FRA-expressing cancer treated by the methods disclosed herein is a metastatic cancer. In some embodiments, metastatic cancer has no genomic changes. In some embodiments, metastatic cancer has at least one genomic change. In some embodiments, at least one genomic change is in at least one of the following genes: EGFR, ALK, PI3K, AKT, mTOR, RET, MET, BRAF, NTRK, ROS1, and any gene involved in the RAS-MAPK pathway. In some embodiments, metastatic cancer is non-small cell lung cancer (NSCLC). In some embodiments, FRA-expressing cancer is a refractory cancer. In some embodiments, refractory cancer is unresponsive to at least one previous treatment, such as an approved treatment, such as a targeted therapy. As used herein, "targeted therapy" is a cancer therapy targeting certain genes and / or proteins involved in cancer cell growth and / or survival. In some embodiments, targeted therapy is a targeted therapy for any of the following genes or variants thereof: EGFR, ALK, BRAF, RET, MET, NTRK, and ROS1. In some embodiments, refractory cancer is unresponsive to approved treatments, such as platinum-based treatments and / or immunotherapy-based treatments (e.g., checkpoint inhibitor therapy). In some embodiments, refractory cancer is unresponsive to platinum-based treatment and immunotherapy-based treatment (e.g., checkpoint inhibitor therapy), wherein these treatments are administered simultaneously or sequentially. In some embodiments, platinum-based treatment is platinum double-drug chemotherapy, and immunotherapy-based treatment is a PD-1 inhibitor or a PD-L1 inhibitor. In various embodiments, refractory cancer is unresponsive to anti-CTLA4 inhibitors. In various embodiments, refractory cancer is unresponsive to radiation therapy. In various embodiments, refractory cancer is unresponsive to surgery. In various embodiments, refractory cancer is unresponsive to chemotherapy. In various embodiments, subjects with refractory cancer are unresponsive to no more than 3 previous systemic therapies, for example, no more than 2 previous systemic therapies. In some embodiments, subjects with refractory cancer are unresponsive to no more than 1 previous chemotherapy.

[0036] In certain embodiments, the subject treated according to the methods disclosed herein does not have one or more of the following: interstitial lung disease (ILD) and / or pneumonia, history of ILD and / or pneumonia, clinically significant lung-specific disease, pleural effusion, pericardial effusion, previous lung resection, history of chest radiotherapy within the past 2 years, autoimmune disorders with lung involvement, connective tissue disorders with lung involvement, or inflammatory disorders with lung involvement. In certain embodiments, the subject treated does not have one or more of the following: a history of more than three previous therapies for FRA-expressing cancers, a high neutrophil to lymphocyte ratio, or a serum albumin level of less than 3 g / dL at the start of treatment. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] Figure 1 The results of the exposure-response (ER) analysis of ORR in subjects with platinum-resistant ovarian cancer (PROC) are shown. Subjects were stratified into exposure quartiles. Points represent the observed median exposure and ORR / quartile. The vertical bars represent the exact 90% confidence interval. The solid curve in the upper sub-figure represents the logistic regression fit. The shaded band in the upper sub-figure represents the 90% confidence interval of the fit.

[0038] Figure 2 Shown are the results of the exposure-response (ER) analysis of ILD in subjects with PROC and across tumor types. Subjects are stratified into exposure quartiles. Points represent observed median exposure and ORR / quartiles. Vertical bars represent precise 90% confidence intervals. The solid curve in the upper sub-figure represents the logistic regression fit of the reference subject with a median age of 60 years old. The shaded band in the upper sub-figure represents the 90% confidence interval of the fit.

[0039] Figure 3 Simulation results for different dosing regimens of MORAb-202 are shown. AIBW = adjusted ideal body weight; BW = body weight; BSA = body surface area. The orange lines in the top graph are LOESS fit error bars. The BW quartiles are indicated by the bracketed values ​​on the x-axis of the bottom graph.

[0040] Figure 4 Shown are predicted median MORAb-202 concentrations over time using a BW-based dosing schedule and a BSA-based dosing schedule.

[0041] Figure 5 Shown is a study design using a BSA-based dosing regimen for subjects with ovarian cancer (OC) and / or endometrial cancer (EC).

[0042] Figure 6 Shown is a study design using a BSA-based dosing regimen for subjects with metastatic non-small cell lung cancer (NSCLC).

[0043] Figure 7 Shown is a study design using a BSA-based dosing regimen for subjects with platinum-resistant high-grade serous ovarian, primary peritoneal, or fallopian tube cancer. DETAILED DESCRIPTION

[0044] The disclosed methods may be more readily understood by reference to the following detailed description in conjunction with the accompanying drawings, which form a part of this disclosure. It should be understood that the present disclosure is not limited to the specific methods described and / or shown herein, and the terminology used herein is only for the purpose of describing specific embodiments by way of example and is not intended to limit the claimed methods.

[0045] Throughout this document, methods involving the use of compositions, such as anti-FRA ADCs, such as MORAb-202, are described. When the disclosure describes or claims features or embodiments associated with methods of using the compositions, such features or embodiments apply equally to the compositions.

[0046] When a range of values ​​is expressed, it includes embodiments using any specific value within the range. In addition, references to values ​​stated in ranges include each value within the range. All ranges include their endpoints and are combinable. When a value is expressed as an approximate value by using "about" in the front, it should be understood that a specific value forms another embodiment. Unless the context clearly indicates otherwise, references to a specific numerical value include at least that specific value. Unless otherwise indicated for its specific use, the use of "or" means "and / or". All references cited herein are incorporated by reference for any purpose. In the event that a reference contradicts this specification, this specification shall prevail.

[0047] It should be understood that certain features of the disclosed method described herein in the context of separate embodiments for the purpose of clarity may also be provided in a single embodiment in a combined form. Conversely, different features of the disclosed method described in the context of a single embodiment for the purpose of brevity may also be provided separately or in any sub-combination.

[0048] Various terms related to the described aspects are used throughout this specification and claims. Unless otherwise indicated, such terms will be given their ordinary meaning in the art. Other specifically defined terms are to be interpreted in a manner consistent with the definitions provided herein.

[0049] As used herein, the singular forms "a", "an" and "the" include plural forms unless the context clearly dictates otherwise.

[0050] As will be apparent to one of ordinary skill in the art from the teachings contained herein, in the context of numerical values ​​and ranges, the term "about" or "approximately" refers to values ​​or ranges that are approximately or close to the recited value or range so that the embodiment can be performed as expected, such as having a desired amount of nucleic acid or polypeptide in the reaction mixture. This is due, at least in part, to the different characteristics of nucleic acid composition, age, race, sex, anatomical and physiological variations, and the imprecision of biological systems. Therefore, these terms encompass values ​​that exceed those produced by systematic errors. It should be understood that the definition of "about" applies to the entire disclosure, unless otherwise specified in certain contexts, for example, when describing the average number of drug moieties for each individual antibody portion or within a mixture of ADCs.

[0051] The term "agent" is used herein to refer to a compound, a mixture of compounds, a biomacromolecule, an extract made from biological material, or a combination thereof. The term "therapeutic agent," "drug," or "drug moiety" refers to an agent that is capable of modulating a biological process and / or has biological activity.

[0052] The term "antibody" is used in the broadest sense to refer to an immunoglobulin molecule that recognizes and specifically binds a target such as a protein, polypeptide, carbohydrate, polynucleotide, lipid, or a combination of the foregoing through at least one antigen recognition site within the variable region of the immunoglobulin molecule. The heavy chain of an antibody comprises a heavy chain variable domain (V H ) and heavy chain constant region (C H The light chain contains a light chain variable domain (V L ) and the light chain constant domain (C L ). For the purposes of this application, the mature heavy and light chain variable domains each comprise three complementary determining regions (CDR1, CDR2 and CDR3) within four framework regions (FR1, FR2, FR3 and FR4) arranged from the N-terminus to the C-terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. An "antibody" may be naturally occurring or artificial, such as a monoclonal antibody produced by conventional hybridoma technology. The term "antibody" includes full-length monoclonal antibodies and full-length polyclonal antibodies, as well as antibody fragments such as Fab, Fab', F(ab')2, Fv, and single-chain antibodies. The antibody may be any of the five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, or subclasses thereof (e.g., isotypes IgG1, IgG2, IgG3, IgG4). The term further encompasses human antibodies, chimeric antibodies, humanized antibodies, and any modified immunoglobulin molecules containing an antigen recognition site, as long as they exhibit the desired biological activity.

[0053] The term "chimeric antibody" as used herein refers to an antibody in which the amino acid sequence of the immunoglobulin molecule is derived from two or more species. In some cases, the variable regions of both the heavy and light chains correspond to the variable regions of an antibody derived from one species with the desired specificity, affinity and activity, while the constant regions are homologous to antibodies derived from another species (e.g., humans) to minimize the immune response in the latter species.

[0054] As used herein, the term "human antibody" refers to an antibody produced by humans or an antibody having the amino acid sequence of an antibody produced by humans.

[0055] As used herein, the term "humanized antibody" refers to an antibody form containing sequences from non-human (e.g., mouse) antibodies and human antibodies. Such antibodies are chimeric antibodies containing minimal sequences derived from non-human immunoglobulins. In general, a humanized antibody will comprise substantially all of at least one and usually two variable domains, wherein all or substantially all hypervariable loops correspond to the hypervariable loops of non-human immunoglobulins and all or substantially all framework (FR) regions are framework regions of human immunoglobulin sequences. Humanized antibodies will optionally also comprise at least a portion of an immunoglobulin constant region (Fc), typically at least a portion of a constant region of a human immunoglobulin. Humanized antibodies can be further modified by substitution of residues in the Fv framework region and / or in the replaced non-human residues to improve and optimize antibody specificity, affinity, and / or activity.

[0056] As used herein, the term "monoclonal antibody" refers to an antibody obtained from a substantially homogeneous antibody population, i.e., the individual antibodies constituting the population are identical except for possible naturally occurring mutations that may be present in small amounts. Monoclonal antibodies are highly specific for a single antigenic epitope. In contrast, conventional (polyclonal) antibody preparations typically include a variety of antibodies specific for different epitopes or to them. The modifier "monoclonal" represents the characteristics of an antibody obtained from a substantially homogeneous antibody population, and should not be interpreted as requiring antibodies to be produced by any particular method. For example, the monoclonal antibodies used according to the present disclosure can be manufactured by the hybridoma method first described by Kohler et al. (1975) Nature [Nature] 256:495, or can be manufactured by recombinant DNA methods (see, e.g., U.S. Patent No. 4,816,567). Monoclonal antibodies can also be isolated from phage antibody libraries using techniques described, for example, in Clackson et al. (1991) Nature 352:624-8 and Marks et al. (1991) J. Mol. Biol. 222:581-97.

[0057] The monoclonal antibodies described herein specifically include "chimeric" antibodies in which a portion of the heavy chain and / or light chain is identical or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of one or more chains is identical or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies; so long as they specifically bind to the target antigen and / or exhibit the desired biological activity.

[0058] The terms "antibody-drug conjugate", "antibody conjugate", "conjugate", "immunoconjugate" and "ADC" are used interchangeably and refer to a compound (e.g., eribulin) or a derivative thereof linked to an antibody (e.g., an anti-FRA antibody) and are defined by the following general formula: Ab-(LD)p (Formula I), wherein Ab = antibody moiety (ie, antibody or antigen-binding fragment), L = linker moiety, D = drug moiety, and p = number of drug moieties per antibody moiety.

[0059] As used herein, the term "antigen-binding fragment" or "antigen-binding portion" of an antibody refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen (e.g., FRA). The antigen-binding fragment preferably also retains the ability to be internalized into antigen-expressing cells. In some embodiments, the antigen-binding fragment also retains immune effector activity. It has been demonstrated that fragments of full-length antibodies can perform the antigen-binding function of full-length antibodies. Examples of binding fragments encompassed within the term "antigen-binding fragment" or "antigen-binding portion" of an antibody include (i) Fab fragments, i.e., fragments consisting of V L Domain, V H Domain, C L Domain and C H1 (ii) a F(ab')2 fragment, i.e. a bivalent fragment comprising two Fab fragments connected by a disulfide bridge at the hinge region; (iii) a fragment consisting of V H Domain and C H1 The Fd fragment consists of the binding domain; (iv) the V L Domain and V H (v) dAb fragments, which contain a single variable domain, such as V H domains (see, e.g., Ward et al. (1989) Nature 341:544-6; and Winter et al., WO 90 / 05144); and (vi) separate complementarity determining regions (CDRs). In addition, although the two domains V L and V H are encoded by separate genes, but they can be joined using recombinant methods via a synthetic linker that enables them to be made as a single protein chain, where V L Area and V HThe regions are paired to form a monovalent molecule (called a single-chain Fv (scFv)). See, e.g., Bird et al., (1988) Science 242:423-6; and Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85:5879-83. Such single-chain antibodies are also included in the term "antigen-binding fragment" or "antigen-binding portion" of an antibody, and are known in the art as an exemplary type of binding fragment that can be internalized into a cell after binding. See, e.g., Zhu et al. (2010) 9:2131-41; He et al. (2010) J Nucl. Med. 51:427-32; and Fitting et al. (2015) MAbs 7:390-402. In certain embodiments, scFv molecules can be incorporated into fusion proteins. Other forms of single-chain antibodies such as bifunctional antibodies are also contemplated. Diabodies are bivalent bispecific antibodies, in which V H and V L The domains are expressed on a single polypeptide chain, but with a linker that is too short to allow pairing between the two domains on the same chain, thereby forcing the domains to pair with the complementary domains of another chain and create two antigen-binding sites (see, e.g., Holliger et al. (1993) Proc. Natl. Acad. Sci. USA [Proceedings of the National Academy of Sciences of the United States] 90:6444-8; and Poljak et al. (1994) Structure [Structure] 2:1121-3). Antigen-binding fragments are obtained using conventional techniques known to those of ordinary skill in the art, and the binding fragments are screened for utility (e.g., binding affinity, internalization) in the same manner as intact antibodies. Antigen-binding fragments can be prepared by cleavage of the intact protein, such as by protease or chemical cleavage.

[0060] As used herein, "body surface area" or "BSA" refers to the total surface area of ​​a subject treated with the methods disclosed herein. The body surface area of ​​a subject can be calculated to determine the most appropriate dose of a compound (e.g., an antibody-drug conjugate, such as an anti-FRA ADC) administered to the subject. In general, the body surface area value of a subject can be calculated based on the subject's weight.

[0061] The term "cancer" refers to a physiological condition in a mammal, wherein the cell colony is characterized by unregulated cell growth. Examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, leukemia, ovarian cancer (e.g., platinum-resistant ovarian cancer), breast cancer (e.g., triple-negative breast cancer), non-small cell lung cancer, endometrial cancer, peritoneal cancer, and fallopian tube cancer. Triple-negative breast cancer refers to breast cancer that is negative for the gene expression of estrogen receptor (ER), progesterone receptor (PR), and Her2 / neu. More specific examples of such cancers include squamous cell carcinoma, small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, peritoneal cancer, hepatocellular carcinoma, gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, liver cancer, bladder cancer, liver cancer, osteosarcoma, melanoma, colon cancer, colorectal cancer, uterine cancer, salivary gland cancer, kidney cancer, liver cancer, prostate cancer, vulvar cancer, thyroid cancer, hepatoepithelial cancer, peritoneal cancer, fallopian tube cancer, and various types of head and neck cancer.

[0062] The terms "cancer cell" and "tumor cell" refer to a single cell or a whole cell population derived from a tumor, including non-tumorigenic cells and cancer stem cells. When only those tumor cells that lack renewal and differentiation capabilities are referred to, the term "tumor cell" as used herein is modified by the term "non-tumorigenic" to distinguish those tumor cells from cancer stem cells.

[0063] The term "chemotherapeutic agent" or "anticancer agent" is used herein to refer to all compounds that are effective in treating cancer, regardless of the mechanism of action. Inhibition of metastasis or angiogenesis is often a property of chemotherapeutic agents. Non-limiting examples of chemotherapeutic agents include alkylating agents, such as nitrogen mustards, ethyleneimine compounds, and alkyl sulfonates; antimetabolites, such as folic acid, purine or pyrimidine antagonists; antimitotic agents, such as antitubulin agents, such as eribulin or eribulin mesylate; TM ) or its derivatives, vinca alkaloids and auristatins; cytotoxic antibiotics; compounds that damage or interfere with DNA expression or replication, such as DNA minor groove binders; and growth factor receptor antagonists. In addition, chemotherapeutic agents include antibodies, biomolecules and small molecules. Chemotherapeutic agents can be cytotoxic agents or cytostatic agents. The term "cytostatic agent" refers to an agent that inhibits or suppresses cell growth and / or cell proliferation.

[0064] The term "co-administration" or administration of one or more therapeutic agents "in combination" includes simultaneous administration as well as consecutive administration in any order.

[0065] As used herein, a "corticosteroid" is any compound belonging to a class of steroid hormones normally produced in the adrenal cortex of vertebrates. The term as used herein further includes synthetic analogs of such hormones, such as pharmaceutical compositions that mimic the effects of naturally occurring corticosteroids. Dexamethasone is an exemplary embodiment of a corticosteroid. Prednisone is also an exemplary embodiment of a corticosteroid. Methylprednisolone is another exemplary embodiment of a corticosteroid.

[0066] The term "cytotoxic agent" refers to a substance that causes cell death primarily by interfering with the expression activity and / or operation of the cell. Examples of cytotoxic agents include, but are not limited to, antimitotic agents such as eribulin, auristatins (e.g., monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF)), maytansine alkaloids (e.g., maytansine), pyrenesin, duostatin, scutellarin, vinca alkaloids (e.g., vincristine, vinblastine), taxanes, paclitaxel, and colchicine; anthracyclines (e.g., daunomycin, doxorubicin, dihydroxyanthr acindione); cytotoxic antibiotics (e.g., mitomycin, actinomycin, duomycin (e.g., CC-1065), auromycin / duomycin, calicheamicin, endomycin, phenomycin); alkylating agents (e.g., cisplatin); intercalating agents (e.g., ethidium bromide); topoisomerase inhibitors (e.g., etoposide, tenoposide); radioactive isotopes, such as At 211 ,I 131 ,I 125 , Y 90 、Re 186 、Re 188 、Sm 153 、Bi 212 Or Bi 213 , P 32 and lutetium radioisotopes (such as Lu 177 ); and toxins of bacterial, fungal, plant or animal origin (e.g., ricin (e.g., ricin A chain), diphtheria toxin, Pseudomonas exotoxin A (e.g., PE40), endotoxin, mitogen, combrestatin, restrictocin, gelonin, α-sarcin, abrin (e.g., abrin A chain), modisin (e.g., modisin A chain), curicin, crotonin, Sapaonaria officinalis inhibitor, glucocorticoids).

[0067] An "effective amount" of an ADC as disclosed herein is an amount sufficient to carry out a specific stated purpose (e.g., to produce a therapeutic effect after administration, such as reducing tumor growth rate or tumor volume, reducing cancer symptoms, or some other indicator of therapeutic efficacy). The effective amount can be determined in a conventional manner related to the stated purpose. The term "therapeutically effective amount" refers to the amount of ADC that effectively treats a disease or disorder in a subject. In the case of cancer, a therapeutically effective amount of an ADC can reduce the number of cancer cells, reduce tumor size, inhibit (e.g., slow down or stop) tumor metastasis, inhibit (e.g., slow down or stop) tumor growth, and / or alleviate one or more symptoms. Therapeutically effective amounts for treatment and therapy include but do not require complete treatment. For example, the term includes but does not require complete cessation of tumor growth.

[0068] The term "epitope" refers to the part of the antigen that can be recognized and specifically bound by an antibody. When the antigen is a polypeptide, the epitope can be formed by continuous amino acids or non-continuous amino acids adjacent to the tertiary folding of the polypeptide. The epitope to which the antibody is bound can be identified using any epitope mapping technique known in the art, including X-ray crystallography (which is by directly visualizing the antigen-antibody complex) for epitope recognition, and monitoring the combination of antibody and antigen fragments or mutant variants, or monitoring the solvent accessibility of different parts of the antibody and antigen. Exemplary strategies for mapping antibody epitopes include, but are not limited to, array-based oligopeptide scanning, restricted proteolysis, site-directed mutagenesis, high-throughput mutagenesis mapping, hydrogen-deuterium exchange, and mass spectrometry (see, e.g., Gershoni et al. (2007) 21: 145-56; and Hager-Braun and Tomer (2005) Expert Rev. Proteomics [proteomics expert review] 2: 745-56).

[0069] As used herein, the term "eribulin" refers to a synthetic analog of halichondria B, a macrocyclic compound originally isolated from the marine sponge Halichondria okadais. The term "eribulin drug moiety" refers to an ADC component having an eribulin structure and connected to a linker of the ADC via its C-35 amine. Eribulin is a microtubule dynamics inhibitor that is believed to bind to tubulin and induce cell cycle arrest in the G2 / M phase by inhibiting mitotic spindle assembly. The term "eribulin mesylate" refers to a ribulin mesylate sold under the trade name Halaven TM Commercially available mesylate salt of eribulin.

[0070] As used herein, the term "folate receptor alpha" or "FRA" refers to any naturally occurring form of human FRA. The term encompasses full-length FRA (e.g., NCBI Reference Sequence: NP_000793; SEQ ID NO: 37), as well as any form of human FRA produced by cell processing. The term also encompasses naturally occurring variants of FRA, including but not limited to splice variants, allelic variants, and isoforms. FRA can be isolated from humans, or can be produced recombinantly or by synthetic methods.

[0071] The term "anti-FRA antibody" or "antibody that specifically binds to FRA" refers to any form of an antibody or fragment thereof that specifically binds to FRA, and encompasses monoclonal antibodies (including full-length monoclonal antibodies), polyclonal antibodies, and biologically functional antibody fragments, as long as such biologically functional antibody fragments specifically bind to FRA. Preferably, the anti-FRA antibody used in the ADC disclosed herein is an internalizing antibody or an internalizing antibody fragment. MORAb-003 is an exemplary internalizing anti-human FRA antibody that can be used in the present disclosure, for example, as part of an anti-FRA ADC. As used herein, the terms "specificity", "specific binding" and "specifically binds" refer to the selective binding of an antibody to a target antigen epitope. The binding specificity of an antibody can be tested by comparing binding to an appropriate antigen and binding to an irrelevant antigen or antigen mixture under a given set of conditions. If the affinity of an antibody binding to an appropriate antigen is at least 2, 5, 7 times and preferably 10 times the affinity of binding to an irrelevant antigen or antigen mixture, it is considered to have specificity. In one embodiment, the specific antibody is an anti-FRA antibody that binds only to the FRA antigen but does not bind (or exhibits minimal binding) to other antigens.

[0072] As used herein with respect to an antibody or antigen-binding fragment, "internalization" refers to the ability of the antibody or antigen-binding fragment to pass through the lipid bilayer membrane of a cell into an internal compartment (i.e., "internalization"), preferably into a degradation compartment in a cell, after binding to a cell. For example, an internalizing anti-FRA antibody is an antibody that is able to be taken up into a cell after binding to FRA on the cell membrane.

[0073] The term "interstitial lung disease" refers to any of a group of lung diseases characterized by inflammation that can lead to pulmonary fibrosis. Interstitial lung disease (ILD) is known to be a potential adverse reaction associated with immunotherapy treatment. An "adverse reaction" or "AE" is any untoward medical event that occurs in a subject to which a compound is administered, and does not necessarily imply a causal relationship with the administered compound or that indicates that the compound cannot be used for treatment, but may limit the use of the compound. Methods for identifying and diagnosing interstitial lung disease are well known in the art, for example, using a pulse oximeter to assess oxygen saturation, and using a chest computed tomography (CT) scan to assess ILD-related lung damage.

[0074] "Linker" or "linker moiety" refers to any chemical moiety that is capable of covalently linking a compound, typically a drug moiety such as a chemotherapeutic, to another moiety, such as an antibody moiety. The linker may be susceptible to or substantially resistant to acid-induced cleavage, peptidase-induced cleavage, light-based cleavage, esterase-induced cleavage, and / or disulfide bond cleavage under conditions that allow the compound or antibody to remain active.

[0075] The term "p" or "antibody:drug ratio" or "drug to antibody ratio" or "DAR" refers to the number of drug moieties per antibody moiety, i.e., drug loading, or the number of -LD moieties per antibody or antigen-binding fragment (Ab) in an ADC having Formula I. In a composition comprising multiple copies of an ADC having Formula I, "p" refers to the average number of -LD moieties per antibody or antigen-binding fragment, also referred to as average drug loading.

[0076] "Pharmaceutically acceptable" means approved or approvable by a regulatory agency of the Federal or a state government or listed in the US Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.

[0077] A "pharmaceutical composition" refers to a preparation that is in a form that permits administration of the active ingredients and subsequently provides the desired biological activity of one or more active ingredients and / or achieves a therapeutic effect, and does not contain additional components that are unacceptably toxic to a subject to which the formulation is administered. The pharmaceutical composition may be sterile.

[0078] "Pharmaceutical excipients" include substances such as adjuvants, carriers, pH adjusters and buffers, tonicity adjusters, wetting agents, preservatives and the like.

[0079] As used herein, "protein" means at least two covalently linked amino acids. The term encompasses polypeptides, oligopeptides and peptides. In some embodiments, two or more covalently linked amino acids are linked by peptide bonds. Proteins can be composed of naturally occurring amino acids and peptide bonds, such as when proteins are made recombinantly using expression systems and host cells. Alternatively, proteins can include synthetic amino acids (e.g., homophenylalanine, citrulline, ornithine and norleucine) or peptide mimetic structures (i.e., "peptide or protein analogs", such as peptoids).

[0080] For amino acid sequences, sequence identity and / or similarity can be determined by using standard techniques known in the art, or by inspection, including, but not limited to, the local sequence identity algorithm of Smith and Waterman, (1981), Adv. Appl. Math. 2:482, the sequence identity alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48:443, the similarity search method of Pearson and Lipman (1988) Proc. Nat. Acad. Sci. USA 85:2444, computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Drive, Madison, Wisconsin), Devereux et al. (1984) Nucl. Acid Software. Res. [Nucleic Acids Research] 12: 387-95 describes the best fit sequence program (preferably using default settings). Preferably, the percent identity is calculated by FastDB based on the following parameters: mismatch penalty 1; gap penalty 1; gap size penalty 0.33; and juncture penalty 30 ("Current Methods in Sequence Comparison and Analysis [Current Sequence Comparison and Analysis Methods]", Macromolecule Sequencing and Synthesis, Selected Methods and Applications [High Molecular Sequencing and Synthesis, Partial Methods and Applications], pp. 127-149 (1988), Alan R. Liss, Inc [Allen Liss Publishing Company]).

[0081] An example of a suitable algorithm is PILEUP. PILEUP uses progressive pairwise alignments to generate a multiple sequence alignment from a group of related sequences. It can also draw a dendrogram showing the cluster relationships used to generate the alignment. PILEUP uses a simplified form of the progressive alignment method of Feng and Doolittle (1987) J. Mol. Evol. [Journal of Molecular Evolution] 35:351-60; this method is similar to the method described by Higgins and Sharp (1989) CABIOS 5:151-3. Suitable PILEUP parameters include a preset gap weight of 3.00, a preset gap length weight of 0.10, and weighted end gaps.

[0082] Another example of a suitable algorithm is the BLAST algorithm described in Altschul et al. (1990) J. Mol. Biol. 215:403-10; Altschul et al. (1997) Nucleic Acids Res. 25:3389-402; and Karin et al. (1993) Proc. Natl. Acad. Sci. USA 90:5873-87. A particularly suitable BLAST program is the WU-BLAST-2 program obtained from Altschul et al. (1996) Methods in Enzymology 266:460-80. WU-BLAST-2 uses several search parameters, most of which are set to default values. The adjustable parameters are set with the following values: overlap interval = 1, overlap fraction = 0.125, word threshold (T) = II. The HSP S and HSP S2 parameters are dynamic values ​​and are established by the program itself depending on the composition of the specific sequence and the composition of the specific database against which the sequence of interest is searched; however, such values ​​can be adjusted to increase sensitivity.

[0083] An additional suitable algorithm is the gapped BLAST reported in Altschul et al. (1993) Nucl. Acids Res. 25:3389-402. Gapped BLAST uses BLOSUM-62 instead of scoring; the threshold T parameter is set to 9; the two-hit method is used to trigger the gapless extension, adding a gap length k at a cost of 10+k; Xu is set to 16, and Xg is set to 40 at the database search stage and to 67 at the algorithm output stage. Gap alignments are triggered by a score corresponding to about 22 ratios.

[0084] Typically, the amino acid homology, similarity or identity between the proteins disclosed herein and their variants (including variants of FRA, and variants of antibody variable domains (including individual variant CDRs)) and the sequences described herein is at least 80%, and more typically preferably has an increased homology or identity of at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, almost 100% or 100%.

[0085] In a similar manner, the "percentage (%) of nucleic acid sequence identity" for the nucleic acid sequences of antibodies and other proteins identified herein is defined as the percentage of nucleotide residues in the candidate sequence that are identical to the nucleotide residues in the coding sequence of the antigen binding protein. The specific method utilizes the BLASTN module of WU-BLAST-2 set to default parameters, wherein the overlap interval and overlap fraction are set to 1 and 0.125, respectively.

[0086] The terms "subject", "patient" and "participant" are used interchangeably herein to refer to any animal, such as any mammal, including but not limited to humans, non-human primates, rodents, etc. In some embodiments, the mammal is a mouse. In some embodiments, the mammal is a human.

[0087] The terms "tumor" and "neoplasm" refer to any mass of tissue, benign or malignant, resulting from excessive cell growth or proliferation, including precancerous lesions.

[0088] As used herein, "treatment" or "therapeutic" and grammatically related terms refer to any improvement of any consequence of a disease, such as prolonged survival, lower morbidity, and / or reduced side effects caused by alternative treatment modalities. As is readily understood in the art, complete eradication is preferred but not required for therapeutic action. As used herein, "treatment" or "treat" refers to administering, for example, the ADC to a subject, such as a patient. Treatment can be curing, healing, alleviating, alleviating, altering, remedying, improving, alleviating, modifying, or affecting a condition, a symptom of a condition, or a predisposition to the condition (e.g., cancer). The terms "treatment" and "therapy" are used interchangeably herein.

[0089] In various embodiments, a method for reducing the risk of interstitial lung disease (ILD) in a subject treated with anti-FRA ADC is provided herein. As used herein, "reducing risk" refers to the change (for example, the change in the number of subjects suffering from ILD) relative to the ILD incidence rate for comparative treatment. For example, compared with similar subjects using anti-FRA ADC in a given time period at the same dose based on body weight, the anti-FRA ADC treatment disclosed herein using the dosing regimen based on BSA can reduce the ILD risk of some subjects.

[0090] As used herein, the term "upper quartile of body weight" refers to a body weight value within the first 25% of all body weight values ​​for a given subject group (e.g., a group of adults in the general population or a group of subjects with FRA-expressing cancers). As used herein, the term includes values ​​representing the boundaries of the first 25%. For example, the upper quartile of body weight for a given subject group can be determined by first arranging the subject's body weight values ​​in ascending order, then dividing the set of values ​​into four equal parts (also referred to as quartiles), and finally determining the value between the third and fourth quartiles. The body weight value of a subject whose body weight is in the upper quartile is at least equal to (if not greater than) the value between the third and fourth quartiles. In some embodiments, the value between the third and fourth quartiles for a given subject group is close to or about 80 kilograms.

[0091] Antibody-drug conjugates

[0092] The methods of the present disclosure include the use of compounds having anticancer activity. In particular, these compounds include an antibody portion (including antigen-binding fragments thereof) conjugated to a drug portion (i.e., covalently linked via a linker), wherein the drug portion, for example, has a cytotoxic or cytostatic effect when not conjugated to the antibody portion. In various embodiments, the drug portion exhibits reduced cytotoxicity or no cytotoxicity when incorporated into the conjugate, but restores cytotoxicity after cleavage from the linker and antibody portion.

[0093] In some embodiments, the ADC comprises a peptide cleavable linker that connects Eribulin to the anti-FRA ADC. In some embodiments, the linker comprises a val-cit portion. In some embodiments, the linker comprises a PEG spacer. In some embodiments, the linker comprises a Mal-(PEG)2-Val-Cit-pAB linker that connects Eribulin to an anti-FRA antibody (e.g., an anti-FRA antibody, such as MORAb-003). In some embodiments, the anti-FRA ADC is MORAb-202. "MORAb-202" refers to an anti-FRA ADC, wherein the anti-FRA antibody or antigen-binding fragment comprises a heavy chain amino acid sequence of SEQ ID NO: 15 and a light chain amino acid sequence of SEQ ID NO: 16, wherein the linker portion comprises Mal-(PEG)2-Val-Cit-pAB, and wherein the linker is connected to Eribulin through the C-35 amine. In some embodiments, the structure of MORAb-202, including the sequence of the anti-FRA antibody portion of the ADC, is disclosed in PCT Application No. PCT / US2017 / 020529 (published as WO 2017 / 151979), which is incorporated herein by reference in its entirety.

[0094] In some embodiments, anti-FRA ADCs (e.g., MORAb-202) exhibit particularly advantageous properties in various categories, such as: (i) the ability to retain one or more therapeutic properties exhibited by separate antibody and drug moieties; (ii) the ability to maintain the specific binding properties of the antibody moiety; (iii) optimization of drug loading and drug to antibody ratio; (iv) the ability to allow delivery (e.g., intracellular delivery) of the drug moiety via stable attachment to the antibody moiety; (v) the ability to maintain the stability of the ADC as a complete conjugate until transport or delivery to the target site; (vi) minimizing aggregation of the ADC before or after administration; (vii) the ability to allow the therapeutic effect (e.g., cytotoxic effect) of the drug moiety to be achieved after cleavage in the cellular environment; (viii) in vivo anti-cancer therapeutic efficacy similar to or superior to that of separate antibody and drug moieties; (ix) minimization of off-target killing caused by the drug moiety; and / or (x) desirable pharmacokinetic and pharmacodynamic properties, formulability, and toxicological / immunological characteristics.

[0095] The ADC compounds disclosed herein can selectively deliver effective doses of cytotoxic agents or cytostatic agents to FRA-expressing cancer cells or FRA-expressing tumor tissues. The disclosed ADCs have been found to have effective cytotoxic and / or cytostatic activity against cells expressing FRA. Exemplary FRA-expressing cancers include, but are not limited to, ovarian cancer (e.g., serous ovarian cancer, clear cell ovarian cancer, or platinum-resistant ovarian cancer), lung cancer (e.g., non-small cell lung cancer, e.g., metastatic non-small cell lung cancer), breast cancer (e.g., triple-negative breast cancer), and endometrial cancer.

[0096] An exemplary ADC has Formula I:

[0097] Ab-(LD) p (I)

[0098] Where Ab = internalizing anti-folate receptor alpha antibody or internalizing antigen-binding fragment thereof, L = cleavable linker moiety, D = drug moiety, and p = number of drug moieties per antibody moiety.

[0099] Antibody

[0100] The antibody portion (Ab) having Formula I includes within its scope any antibody or antigen-binding fragment that specifically binds to FRA on a cancer cell. The antibody or antigen-binding fragment may bind to FRA with a dissociation constant (K D ) is ≤1 mM, ≤100 nM or ≤10 nM, or any amount therebetween, as determined by, for example In certain embodiments, K D In some embodiments, K DBetween 500 pM and 1 μM, 1 μM and 100 nM, or 100 mM and 10 nM.

[0101] In some embodiments, the antibody portion is a four-chain antibody (also called an immunoglobulin) comprising two heavy chains and two light chains. In some embodiments, the antibody portion is a two-chain half antibody (one light chain and one heavy chain) or an antigen-binding fragment of an immunoglobulin.

[0102] In some embodiments, the antibody portion is an internalizing antibody or an internalizing antigen binding fragment thereof. In some embodiments, the internalizing antibody binds to FRA expressed on the cell surface and enters the cell after binding. In some embodiments, the FRA targeting antibody portion is MORAb-003. In some embodiments, the ADC portion is released from the antibody portion of the ADC after the ADC enters and is present in cells expressing the target cancer antigen (i.e., after the ADC has been internalized).

[0103] The amino acid and nucleic acid sequences of exemplary antibodies that can be used in the ADCs disclosed herein are listed in Tables 1-9.

[0104] Table 1. Antibodies

[0105] mAbs Class / isotype Target MORAb-003 Humanization Human folate receptor alpha

[0106] Table 2. Amino acid sequences of mAb variable regions

[0107]

[0108]

[0109] Table 3. Nucleic acid sequences encoding mAb variable domains

[0110]

[0111] Table 4. Amino acid sequences of mAb Kabat CDRs

[0112]

[0113] Table 5. Nucleic acid sequences encoding mAb Kabat CDRs

[0114]

[0115] Table 6. Amino acid sequences of mAb IMGT CDRs

[0116]

[0117]

[0118] Table 7. Nucleic acid sequences encoding mAb IMGT CDRs

[0119]

[0120] Table 8. Amino acid sequences of full-length mAb Ig chains

[0121]

[0122]

[0123] Table 9. Nucleic acid sequences encoding full-length mAb Ig chains +

[0124]

[0125]

[0126]

[0127]

[0128]

[0129] + The nucleic acid sequences listed do not include the leader sequence.

[0130] In various embodiments, the ADC disclosed herein may include a set of MORAb-003 heavy chain and light chain variable domains listed in the above table, or a set of six MORAb-003 CDR sequences (Kabat and / or IMGT) from the heavy and light chains listed in the above table. In some embodiments, the ADC further comprises human heavy and light chain constant domains or fragments thereof. For example, the ADC may comprise a human IgG heavy chain constant domain (such as IgG1) and a human K or λ light chain constant domain. In various embodiments, the antibody portion of the described ADC comprises a human immunoglobulin G subtype 1 (IgG1) heavy chain constant domain and a human IgK light chain constant domain. In some embodiments, the anti-FRA antibody portion in the ADC comprises the complete heavy and light chain sequences listed in the above table.

[0131] In various embodiments, the anti-FRA antibody or antigen-binding fragment thereof comprises the following three heavy chain CDRs and three light chain CDRs: a heavy chain CDR1 (HCDR1) comprising SEQ ID NO: 1, a heavy chain CDR2 (HCDR2) comprising SEQ ID NO: 2, a heavy chain CDR3 (HCDR3) comprising SEQ ID NO: 3; a light chain CDR1 (LCDR1) comprising SEQ ID NO: 4, a light chain CDR2 (LCDR2) comprising SEQ ID NO: 5, and a light chain CDR3 (LCDR3) comprising SEQ ID NO: 6, as defined by the Kabat numbering system (Kabat, Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, MD (1987 and 1991))).

[0132] In some embodiments, the anti-FRA antibody or antigen-binding fragment thereof comprises the following three heavy chain CDRs and three light chain CDRs: a heavy chain CDR1 comprising SEQ ID NO: 7, a heavy chain CDR2 comprising SEQ ID NO: 8, a heavy chain CDR3 comprising SEQ ID NO: 9; a light chain CDR1 comprising SEQ ID NO: 10, a light chain CDR2 comprising SEQ ID NO: 11, and a light chain CDR3 comprising SEQ ID NO: 12, as defined by the IMGT numbering system (International Immunogenetics Information System). ).

[0133] In various embodiments, the anti-FRA antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 13 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 14. In some embodiments, the anti-FRA antibody or antigen-binding fragment thereof comprises a heavy chain variable region amino acid sequence of SEQ ID NO: 13 and a light chain variable region amino acid sequence of SEQ ID NO: 14, or a sequence having at least 95% identity thereto. In some embodiments, the anti-FRA antibody or antigen-binding fragment thereof has a heavy chain variable region amino acid sequence having at least 96%, at least 97%, at least 98%, or at least 99% identity to SEQ ID NO: 13 and a light chain variable region amino acid sequence having at least 96%, at least 97%, at least 98%, or at least 99% identity to SEQ ID NO: 14.

[0134] In various embodiments, the anti-FRA antibody comprises a human IgG1 heavy chain constant domain and a human Igκ light chain constant domain.

[0135] In various embodiments, the anti-FRA antibody comprises a heavy chain amino acid sequence of SEQ ID NO: 15, or a sequence having at least 95% identity to SEQ ID NO: 15, and a light chain amino acid sequence of SEQ ID NO: 16, or a sequence having at least 95% identity to SEQ ID NO: 16. In specific embodiments, the antibody comprises a heavy chain amino acid sequence of SEQ ID NO: 15 and a light chain amino acid sequence of SEQ ID NO: 16, or a sequence having at least 95% identity to the above sequences. In some embodiments, the anti-FRA antibody has a heavy chain amino acid sequence having at least 96%, at least 97%, at least 98% or at least 99% identity to SEQ ID NO: 15 and / or a light chain amino acid sequence having at least 96%, at least 97%, at least 98% or at least 99% identity to SEQ ID NO: 16. In some embodiments, the anti-FRA antibody comprises a heavy chain amino acid sequence of SEQ ID NO: 15 and a light chain amino acid sequence of SEQ ID NO: 16. In some embodiments, the anti-FRA antibody comprises a heavy chain encoded by a nucleotide sequence of SEQ ID NO: 35 (with nucleotides encoding a leader sequence) or SEQ ID NO: 31 (without nucleotides encoding a leader sequence); and a light chain encoded by a nucleotide sequence of SEQ ID NO: 36 (with nucleotides encoding a leader sequence) or SEQ ID NO: 32 (without nucleotides encoding a leader sequence). In some embodiments, the heavy chain amino acid sequence lacks a C-terminal lysine. In various embodiments, the anti-FRA antibody has the amino acid sequence of an antibody produced by the following cell line, or such sequence lacking a heavy chain C-terminal lysine: the cell line was deposited under the terms of the Budapest Treaty on April 24, 2006 with the American Type Culture Collection (ATCC, 10801 University Blvd., Manassas, Va., 20110-2209), with accession number PTA-7552. In various embodiments, the anti-FRA antibody is MORAb-003 (USAN name: farletuzumab) (Ebel et al. (2007) Cancer Immunity 7:6), or an antigen-binding fragment thereof.

[0136] In various embodiments, amino acid substitutions have a single residue. Insertions are generally in the order of about 1 to about 20 amino acid residues, although considerable insertions may be tolerated as long as the biological function of the anti-FRA is retained. Deletions are generally in the range of about 1 to about 20 amino acid residues, but in some cases, deletions may be much larger. Substitution, deletion, insertion, or any combination thereof may be used to obtain final derivatives or variants. Generally, these changes are carried out on a few amino acids, thereby minimizing the changes in the molecule, particularly the immunogenicity and specificity of the antigen-binding protein. However, in some cases, more changes may be tolerated. Conservative substitutions are generally carried out according to the following charts as described in Table 10.

[0137] Table 10

[0138] Original residue Exemplary substitutions Ala Ser Arg Lys Asn Gln、His Asp Glu Cys Ser Gln Asn Glu Asp Gly Pro His Asn、Gln Ile Leu, Val Leu Ile, Val Lys Arg, Gln, Glu Met Leu, Ile Phe Met, Leu, Tyr Ser Thr Thr Ser Trp Tyr Tyr Trp、Phe Val Ile, Leu

[0139] In some embodiments, the FRA targeting antibody portion is MORAb-003. In some embodiments, FRA targeting antibody portions such as MORAb-003 provide particularly improved drug: antibody ratio, tumor targeting, bystander killing, therapeutic efficacy, and reduced off-target killing. Improved therapeutic efficacy can be measured in vitro or in vivo and can include slowed tumor growth rate and / or reduced tumor volume.

[0140] Connectors

[0141] In various embodiments, the linker in the anti-FRA ADC is extracellularly stable in a manner sufficient to be therapeutically effective. In some embodiments, the linker is stable outside the cell so that the ADC remains intact when present in extracellular conditions (e.g., before being transported or delivered to FRA-expressing cells). The term "intact" used in the context of the ADC refers to the antibody portion remaining connected to the drug portion. As used herein, in the case of a linker or an ADC comprising a linker, "stable" means that when the ADC is present in extracellular conditions, no more than 20%, no more than about 15%, no more than about 10%, no more than about 5%, no more than about 3%, or no more than about 1% (or any percentage therebetween) of the linker in the ADC sample is cut (or in the case where the overall ADC is otherwise incomplete).

[0142] Whether the linker is stable outside the cell can be determined, for example, by including an anti-FRA ADC in plasma for a predetermined period of time (e.g., 2, 4, 6, 8, 16, or 24 hours) and then quantifying the amount of free drug moiety present in the plasma. Stability can allow the ADC time to localize to the target cancer cells and prevent premature release of the drug, which may reduce the therapeutic index of the ADC by indiscriminately damaging both normal and cancerous tissues. In some embodiments, the linker is stable outside the target cell and releases the drug moiety from the ADC once inside the cell so that the drug moiety can bind to its target (e.g., bind to a microtubule). Therefore, an effective linker will: (i) maintain the specific binding properties of the antibody moiety; (ii) allow the drug moiety to be delivered (e.g., intracellular delivery) via stable attachment to the antibody moiety; (iii) maintain stability and integrity until the ADC has been transported or delivered to the target site; and (iv) allow the therapeutic effect of the drug moiety after cleavage, e.g., cytotoxic effect.

[0143] Linkers can be "cleavable" or "non-cleavable" (Ducry and Stump Bioconjugate Chem. (2010) 21:5-13). Cleavable linkers are designed to release the drug when subjected to certain environmental factors (e.g., when internalized into target cells), while non-cleavable linkers generally rely on degradation of the antibody portion itself.

[0144] In some embodiments, the linker is a cleavable linker. A cleavable linker refers to any linker comprising a cleavable portion. As used herein, the term "cleavable portion" refers to any chemical bond that can be cleaved. Suitable cleavable chemical bonds are well known in the art and include, but are not limited to, acid-labile bonds, protease / peptidase-labile bonds, photolabile bonds, disulfide bonds, and esterase-labile bonds. A linker comprising a cleavable portion can allow the drug portion to be released from the ADC via cleavage at a specific site in the linker. In various embodiments, the anti-FRA antibody cleaves the activated or increased activity of the toxin from the connected toxin.

[0145] In some embodiments, the linker can be cleaved by a cleavage agent (e.g., an enzyme) present in the intracellular environment (e.g., a lysosome or endosome or caveolae). The linker can be, for example, a peptide linker that is cleaved by an intracellular peptidase or protease (including but not limited to a lysosomal or endosomal protease). In some embodiments, the linker is a cleavable peptide linker. As used herein, a cleavable peptide linker refers to any linker comprising a cleavable peptide portion. The term "cleavable peptide portion" refers to any chemically bonded amino acids (natural or synthetic amino acid derivatives) that can be cleaved by an agent present in the intracellular environment. For example, the linker can comprise a valine-citrulline (Val-Cit) sequence that can be cleaved by a peptidase such as a cathepsin, such as cathepsin B.

[0146] In some embodiments, the linker is an enzyme cleavable linker and the cleavable peptide portion of the linker can be cleaved by an enzyme. In some embodiments, the cleavable peptide portion can be cleaved by cathepsin B. An exemplary dipeptide that can be cleaved by cathepsin B is valine-citrulline (Val-Cit) (Dubowchik et al. (2002) Bioconjugate Chem. [Bioconjugate Chemistry] 13: 855-69).

[0147] In some embodiments, the linker or the cleavable peptide portion in the linker comprises an amino acid unit. In some embodiments, the amino acid unit makes the linker cleavable by a protease, thereby promoting the release of the drug portion from the ADC when exposed to one or more intracellular proteases (such as one or more lysosomal enzymes) (Doronina et al. (2003) Nat. Biotechnol. [Nature Biotechnology] 21: 778-84; Dubowchik and Walker (1999) Pharm. Therapeutics [Drug Therapy] 83: 67-123). Exemplary amino acid units include, but are not limited to, dipeptides. Exemplary dipeptides include, but are not limited to, valine-citrulline (Val-Cit). In some embodiments, the amino acid unit in the linker comprises Val-Cit. The amino acid unit may comprise naturally occurring amino acid residues and / or secondary amino acids and / or non-naturally occurring amino acid analogs (such as citrulline).

[0148] In some embodiments, the linker in the anti-FRA ADC disclosed herein comprises at least one spacer unit that connects the antibody portion to the drug portion. In some embodiments, the spacer unit connects the cleavage site (e.g., cleavable peptide portion) in the linker to the antibody portion. In some embodiments, the linker comprises one or more polyethylene glycol (PEG) moieties, such as 1, 2, 3, 4, 5, or 6 PEG moieties. In some embodiments, the linker comprises 2 PEG moieties.

[0149] In some embodiments, the spacer unit in the linker comprises one or more PEG moieties. In some embodiments, the spacer unit comprises -(PEG) m -, and m is 2. In some embodiments, the spacer unit comprises (PEG)2.

[0150] In some embodiments, the Spacer unit indirectly links the antibody moiety to the drug moiety. In some embodiments, the Spacer unit indirectly links the antibody moiety to the drug moiety via a cleavable peptide moiety and a linking moiety to link the Spacer unit to the antibody moiety, such as a maleimide moiety.

[0151] In various embodiments, the Spacer unit is linked to the anti-FRA antibody portion (ie, anti-FRA antibody or antigen-binding fragment thereof) through a maleimide moiety (Mal).

[0152] The spacer unit connected to the antibody or antigen binding fragment via Mal is referred to herein as a "Mal-spacer unit". As used herein, the term "maleimide moiety" means a compound containing a maleimide group and reactive with a sulfhydryl group (e.g., a sulfhydryl group of a cysteine ​​residue on an antibody moiety). In some embodiments, the Mal-spacer unit can react with a cysteine ​​residue on an antibody or antigen binding fragment. In some embodiments, the Mal-spacer unit is attached to the antibody or antigen binding fragment via a cysteine ​​residue. In some embodiments, the Mal-spacer unit comprises a (PEG)2 moiety.

[0153] In certain embodiments, the linker comprises a Mal-spacer unit and a cleavable peptide portion. In some embodiments, the cleavable peptide portion comprises an amino acid unit. In some embodiments, the amino acid unit comprises Val-Cit. In some embodiments, the linker comprises Mal-(PEG)2 and Val-Cit.

[0154] In some embodiments, the Mal-spacer unit connects the anti-FRA antibody portion (i.e., an anti-FRA antibody or antigen-binding fragment thereof) to a cleavable portion in the linker. In some embodiments, the Mal-spacer unit connects the antibody or antigen-binding fragment to a cleavable peptide portion. In some embodiments, the cleavable peptide portion comprises an amino acid unit. In some embodiments, the linker comprises a Mal-spacer unit-amino acid unit. In some embodiments, the Mal-spacer unit comprises a PEG portion. In some embodiments, the amino acid unit comprises a Val-Cit.

[0155] In some embodiments, the linker comprises the following structure: Mal-Spacer unit-Val-Cit. In some embodiments, the linker comprises the following structure: Mal-(PEG)2-Val-Cit. In some embodiments, the linker comprises the following structure: Mal-(PEG)2-Val-Cit-pAB.

[0156] In some embodiments, another spacer unit is used to connect the cleavable portion in the linker to the drug portion, such as eribulin. In some embodiments, eribulin is connected to the cleavable portion in the linker via a self-ablative spacer unit. In certain embodiments, eribulin is connected to the cleavable portion in the linker via a self-ablative spacer unit, the cleavable portion comprises Val-Cit, and another spacer unit comprising (PEG)2 connects the cleavable portion to the anti-FRA antibody portion. In certain embodiments, eribulin is connected to the anti-FRA antibody via a Mal spacer unit in the linker, and the Mal spacer unit in the linker is connected to the Val-Cit cleavable portion and the pAB self-ablative spacer unit.

[0157] The spacer unit may be a "self-ablative" or "non-self-ablative" spacer unit. A "non-self-ablative" spacer unit is a spacer unit in which a portion or all of the spacer unit is still bound to the drug portion when the linker is cut. Examples of non-self-ablative spacer units include, but are not limited to, glycine spacer units and glycine-glycine spacer units. Non-self-ablative spacer units may eventually degrade over time, but will not easily and completely release the connected natural drug under cellular conditions. "Self-ablative" spacer units allow the release of the natural drug portion under intracellular conditions. "Natural drug" is a natural drug that does not retain part of the spacer unit or other chemical modifications after the spacer unit is cut / degraded.

[0158] Self-ablative chemistries are known in the art and can be readily selected for the disclosed ADCs. In various embodiments, the spacer unit connecting the cleavable moiety in the linker to the drug moiety (e.g., eribulin) is self-ablative and undergoes self-ablation simultaneously with or shortly before / after cleavage of the cleavable moiety under intracellular conditions.

[0159] In certain embodiments, the self-immolative spacer unit in the linker comprises a p-aminobenzyl unit. In some embodiments, p-aminobenzyl alcohol (pABOH) is linked to an amino acid unit or other cleavable moiety in the linker via an amide bond, and a carbamate, methyl carbamate, or carbonate is made between pABOH and the drug moiety (Hamann et al. (2005) Expert Opin. Ther Patents 15: 1087-103). In some embodiments, the self-immolative spacer unit is or comprises p-aminobenzyloxycarbonyl (pAB). Without being bound by theory, it is believed that self-immolation of pAB involves a spontaneous 1,6-elimination reaction (Jain et al. (2015) Pharm Res 32: 3526-40).

[0160] In various embodiments, the structure of p-aminobenzyloxycarbonyl (pAB) used in the disclosed ADCs is shown below:

[0161]

[0162] p-Aminobenzyloxycarbonyl

[0163] In various embodiments, the self-ablative spacer unit connects the cleavable moiety in the linker to the C-35 amine or eribulin. In some embodiments, the self-ablative spacer unit is pAB. In some embodiments, pAB connects the cleavable moiety in the linker to the C-35 amine or eribulin. In some embodiments, pAB undergoes self-ablation after cleavage of the cleavable moiety, and eribulin is released from the ADC in its native, active form. In some embodiments, an anti-FRA antibody (e.g., MORAb-003) is linked to the C-35 amine of eribulin via a linker comprising Mal-(PEG)2-Val-Cit-pAB.

[0164] In some embodiments, after the cleavage of the cleavable peptide portion in the linker, pAB undergoes self-ablation. In some embodiments, the cleavable peptide portion comprises an amino acid unit. In some embodiments, the linker comprises an amino acid unit-pAB. In some embodiments, the amino acid unit is Val-Cit. In some embodiments, the linker comprises Val-Cit-pAB (VCP). In various other aspects, the antibody portion in the ADC is conjugated to the drug portion via a linker, wherein the linker comprises a Mal-spacer unit, a cleavable amino acid unit, and pAB. In some embodiments, the spacer unit comprises a PEG portion. In some embodiments, the linker comprises Mal-(PEG)2-Val-Cit-pAB.

[0165] In some embodiments, the antibody portion is conjugated to the drug portion via a linker comprising a maleimide portion (Mal), a polyethylene glycol (PEG) portion, a valine citrulline (Val-Cit or "vc"), and pAB. In these embodiments, the maleimide portion covalently links the linker drug portion to the antibody portion, and pAB serves as a self-ablative spacer unit. Such linkers may be referred to as "m-vc-pAB" linkers, "Mal-VCP" linkers, "Mal-(PEG)2-VCP" linkers, or "Mal-(PEG)2-Val-Cit-pAB" linkers. In some embodiments, the drug portion is eribulin. The structure of Mal-(PEG)2-Val-Cit-pAB-eribulin is provided below. The pAB of the Mal-(PEG)2-Val-Cit-pAB linker is linked to the C-35 amine on eribulin.

[0166]

[0167] It has been found that ADCs comprising Mal-(PEG)2-Val-Cit-pAB-eribulin exhibit a particular combination of desirable properties, particularly when paired with an anti-FRA antibody such as MORAb-003 or an antigen-binding fragment thereof. These functional properties are also illustrated in the examples provided in PCT Application No. PCT / US2017 / 020529 (published as WO 2017 / 151979), which is incorporated herein by reference in its entirety.

[0168] In some embodiments, the ADC comprises Mal-(PEG)2-Val-Cit-pAB-Eribulin and an antibody portion comprising an internalizing anti-FRA antibody or an antigen-binding fragment thereof that retains the ability to be targeted and internalized in tumor cells. In some embodiments, the ADC comprises Mal-(PEG)2-Val-Cit-pAB-Eribulin and an internalizing anti-FRA antibody or an internalizing antigen-binding fragment thereof that targets FRA-expressing tumor cells. In some embodiments, the internalizing antibody or internalizing antigen-binding fragment thereof targeted to FRA-expressing tumor cells comprises three heavy chain complementarity determining regions (HCDRs) comprising the amino acid sequences of SEQ ID NO: 1 (HCDR1), SEQ ID NO: 2 (HCDR2), and SEQ ID NO: 3 (HCDR3); and three light chain complementarity determining regions (LCDRs) comprising the amino acid sequences of SEQ ID NO: 4 (LCDR1), SEQ ID NO: 5 (LCDR2), and SEQ ID NO: 6 (LCDR3), as defined by the Kabat numbering system; or three heavy chain complementarity determining regions (HCDRs) comprising the amino acid sequences of SEQ ID NO: 7 (HCDR1), SEQ ID NO: 8 (HCDR2), and SEQ ID NO: 9 (HCDR3); and three light chain complementarity determining regions (LCDRs) comprising the amino acid sequences of SEQ ID NO: 10 (LCDR1), SEQ ID NO: 11 (LCDR2), and SEQ ID NO: 12 (LCDR3), as defined by the IMGT numbering system. In some embodiments, the internalizing antibody or internalizing antigen-binding fragment thereof targeted to FRA-expressing tumor cells comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 13 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 14. In some embodiments, the internalizing antibody or internalizing antigen-binding fragment thereof targeted to FRA-expressing tumor cells comprises a human IgG1 heavy chain constant domain and an Igκ light chain constant domain.

[0169] In some embodiments, the ADC has Formula I:

[0170] Ab-(LD) p (I)

[0171] in:

[0172] (i) Ab is an internalizing anti-folate receptor alpha (FRA) antibody or an internalizing antigen-binding fragment thereof comprising: three heavy chain complementary determining regions (HCDRs) comprising the amino acid sequences of SEQ ID NO: 1 (HCDR1), SEQ ID NO: 2 (HCDR2), and SEQ ID NO: 3 (HCDR3); and three light chain complementary determining regions (LCDRs) comprising the amino acid sequences of SEQ ID NO: 4 (LCDR1), SEQ ID NO: 5 (LCDR2), and SEQ ID NO: 6 (LCDR3), as defined by the Kabat numbering system; or three heavy chain complementary determining regions (HCDRs) comprising the amino acid sequences of SEQ ID NO: 7 (HCDR1), SEQ ID NO: 8 (HCDR2), and SEQ ID NO: 9 (HCDR3); and three light chain complementary determining regions (LCDRs) comprising the amino acid sequences of SEQ ID NO: 10 (LCDR1), SEQ ID NO: 11 (LCDR2), and SEQ ID NO: 12 (LCDR3), as defined by the IMGT numbering system;

[0173] (ii) D is eribulin;

[0174] (iii) L is a cleavable linker comprising Mal-(PEG)2-Val-Cit-pAB; and

[0175] (iv) p is an integer from 1 to 20.

[0176] In some embodiments, the internalizing antibody or internalizing antigen-binding fragment thereof comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 13 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 14. In some embodiments, the internalizing antibody is MORAb-003. In some embodiments, p is 1 to 8, or 1 to 6. In some embodiments, p is 2 to 8, or 2 to 5. In some embodiments, p is 3 to 4. In some embodiments, p is 4.

[0177] Drug section

[0178] The drug portion (D) of the ADCs described herein is an anti-tubulin agent, such as eribulin.

[0179] In some embodiments, the drug moiety is eribulin and the linker of the ADC is attached through the C-35 amine on eribulin.

[0180] In various embodiments, the native form of Eribulin for attachment to the linker and antibody moieties is as follows:

[0181]

[0182] In certain embodiments, the ADC is prepared by reacting an intermediate that is a precursor to a linker with eribulin under appropriate conditions. In certain embodiments, a reactive group is used on eribulin and / or the intermediate or linker. The reaction product between eribulin and the intermediate is then reacted with an anti-FRA antibody or antigen-binding fragment under appropriate conditions. Alternatively, the linker or intermediate may first react with the antibody or derivatized antibody and then react with eribulin.

[0183] Many different reactions can be used for the covalent attachment of eribulin and / or linkers to the antibody portion. This is typically accomplished by the reaction of one or more amino acid residues of the antibody molecule (e.g., the sulfhydryl group of cysteine). For example, nonspecific covalent attachment can be performed using a carbodiimide reaction to attach a carboxyl (or amino) group on the compound to an amino (or carboxyl) group on the antibody portion. Additionally, bifunctional reagents such as dialdehydes or imidoesters can also be used to attach an amino group on the compound to an amino group on the antibody portion. Schiff base reactions can also be used to attach drugs to binding agents. This method involves periodate oxidation of a drug containing a diol or hydroxyl group to form an aldehyde, which is then reacted with the binding agent. Attachment occurs via the formation of a Schiff base with an amine group of the binding agent. Isothiocyanates can also be used as coupling agents for covalently attaching drugs to binding agents. Other techniques are known to those of ordinary skill in the art and are within the scope of this disclosure.

[0184] Drug loading

[0185] Drug loading is represented by p, and is also referred to herein as drug to antibody ratio (DAR). Drug loading can be in the range of 1 to 20 drug moieties per antibody moiety. In some embodiments, p is an integer from 1 to 20. In some embodiments, p is an integer from 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, or 1 to 2. In some embodiments, p is an integer from 2 to 10, 2 to 9, 2 to 8, 2 to 7, 2 to 6, 2 to 5, 2 to 4, or 2 to 3. In some embodiments, p is an integer from 3 to 4. In other embodiments, p is 1, 2, 3, 4, 5, or 6, preferably 3 or 4.

[0186] Drug loading can be limited by the number of connection sites on the antibody portion. In certain embodiments, the linker portion (L) of ADC is connected to the antibody portion via a chemically active group on one or more amino acid residues on the antibody portion. For example, the linker can be connected to the antibody portion (e.g., connected to the N-terminal or C-terminal, connected to the ε amino group of one or more lysine residues, connected to the free carboxylic acid group of one or more glutamic acid or aspartic acid residues, or connected to the sulfhydryl group of one or more cysteine ​​residues) via a free amino group, an imino group, a hydroxyl group, a thiol group or a carboxyl group. The site connected to the linker can be a natural residue in the amino acid sequence of the antibody portion, or it can be introduced into the antibody portion, for example, by DNA recombination technology (e.g., by introducing cysteine ​​residues into the amino acid sequence) or by protein biochemistry (e.g., by reduction, pH adjustment or hydrolysis).

[0187] In some embodiments, the number of drug moieties that can be conjugated to the anti-FRA antibody portion is limited by the number of free cysteine ​​residues. For example, in the case of a cysteine ​​thiol group connected, the anti-FRA antibody may have only one or several cysteine ​​thiol groups, or may have only one or several linkers that can be connected via it with sufficient reactivity thiol groups. Typically, antibodies do not contain many free reactive cysteine ​​thiol groups that can be connected to the drug moiety. In fact, most cysteine ​​thiol residues in antibodies exist as disulfide bonds. Excessive connection of linkers-toxins to antibodies can destabilize the antibody by reducing the cysteine ​​residues available for forming disulfide bridges. Therefore, the optimal drug: antibody ratio should increase the efficacy of the ADC (by increasing the number of drug moieties connected to each antibody) without destabilizing the antibody portion. In some embodiments, the optimal ratio may be about 3-4.

[0188] In some embodiments, a linker connected to the antibody portion via a Mal moiety provides a ratio of about 3-4. In some embodiments, a linker comprising a short spacer unit (e.g., a short PEG spacer unit such as (PEG)2) provides a ratio of about 3-4. In some embodiments, a linker comprising a peptide cleavable moiety provides a ratio of about 3-4. In some embodiments, an ADC comprising Mal-(PEG)2-Val-Cit-pAB-Eribulin connected to an anti-FRA antibody such as MORAb-003 has a ratio of about 3-4.

[0189] In some embodiments, the antibody portion, such as MORAb-003, is exposed to reducing conditions prior to conjugation to generate one or more free cysteine ​​residues. In some embodiments, the antibody can be reduced with a reducing agent such as dithiothreitol (DTT) or tris (2-carboxyethyl) phosphine (TCEP) under partial or total reducing conditions to generate reactive cysteine ​​thiol groups. In certain embodiments, the antibody can be subjected to denaturing conditions to reveal reactive nucleophilic groups on amino acid residues such as lysine or cysteine.

[0190] In a reaction mixture comprising multiple copies of an antibody portion and a linker portion, when more than one nucleophilic group reacts with a drug-linker intermediate or a linker portion reagent and then reacts with a drug portion reagent, the resulting product may be a mixture of ADC compounds, in which one or more drug portions of each copy of the antibody portion connected to the mixture are distributed. In some embodiments, the drug load in the ADC mixture obtained by the conjugation reaction is within the range of 1 to 20 connected drug portions / antibody portions. The average number of drug portions / antibody portions (i.e., average drug load or average p) can be calculated by any conventional method known in the art, such as by mass spectrometry (e.g., reverse phase LC-MS) and / or high performance liquid chromatography (e.g., HIC-HPLC). In some embodiments, the average number of drug portions / antibody portions is determined by hydrophobic interaction chromatography-high performance liquid chromatography (HIC-HPLC). In some embodiments, the average number of drug portions / antibody portions is determined by reverse phase liquid chromatography-mass spectrometry (LC-MS). In some embodiments, the average number of drug moieties per antibody moiety is from about 3 to about 4; from about 3.1 to about 3.9; from about 3.2 to about 3.8; from about 3.2 to about 3.7; from about 3.2 to about 3.6; from about 3.3 to about 3.8; or from about 3.3 to about 3.7. In some embodiments, the average number of drug moieties per antibody moiety is from about 3.2 to about 3.8. In some embodiments, the average number of drug moieties per antibody moiety is about 3.8. In some embodiments, the average number of drug moieties per antibody moiety is from 3 to 4; from 3.1 to 3.9; from 3.2 to 3.8; from 3.2 to 3.7; from 3.2 to 3.6; from 3.3 to 3.8; or from 3.3 to 3.7. In some embodiments, the average number of drug moieties per antibody moiety is from 3.2 to 3.8. In some embodiments, the average number of drug moieties per antibody moiety is 3.8.

[0191] In some embodiments, the average number of drug moieties per antibody moiety is from about 3.5 to about 4.5; from about 3.6 to about 4.4; from about 3.7 to about 4.3; from about 3.7 to about 4.2; or from about 3.8 to about 4.2. In some embodiments, the average number of drug moieties per antibody moiety is from about 3.6 to about 4.4. In some embodiments, the average number of drug moieties per antibody moiety is about 4.0. In some embodiments, the average number of drug moieties per antibody moiety is from 3.5 to 4.5; from 3.6 to 4.4; from 3.7 to 4.3; from 3.7 to 4.2; or from 3.8 to 4.2. In some embodiments, the average number of drug moieties per antibody moiety is from 3.6 to 4.4. In some embodiments, the average number of drug moieties per antibody moiety is 4.0.

[0192] In various embodiments, the term "about" used with respect to the average number of drug moieties in each individual antibody portion or ADC mixture refers to + / - 10%. It should be understood that in this disclosure, the definition of "about" applies to all descriptions of the average number of drug moieties in each individual antibody portion or ADC mixture.

[0193] Individual ADC complexes or "species" having specific DAR ratios can be identified in a mixture by mass spectrometry and separated by UPLC or HPLC, e.g., hydrophobic interaction chromatography (HIC-HPLC). In certain embodiments, homogeneous or near-homogeneous ADCs having a single loading value can be separated from a conjugated mixture, e.g., by electrophoresis or chromatography.

[0194] In some embodiments, the drug load and / or average drug load in the ADC (e.g., in MORAb-202) is about 4. In some embodiments, a drug load and / or average drug load of about 4 provides beneficial properties. See, e.g., PCT / US2017 / 020529 (published as WO 2017 / 151979), which is incorporated herein by reference in its entirety.

[0195] In some embodiments, the ADC has Formula I:

[0196] Ab-(LD) p (I)

[0197] in:

[0198] (i) Ab is an internalizing anti-folate receptor alpha antibody or an antigen-binding fragment thereof comprising: a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 13 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 14;

[0199] (ii) D is eribulin;

[0200] (iii) L is a cleavable linker comprising Mal-(PEG)2-Val-Cit-pAB; and

[0201] (iv) p is an integer from 1 to 8.

[0202] In some embodiments, the ADC has Formula I:

[0203] Ab-(LD) p (I)

[0204] in:

[0205] (i) Ab is an internalizing anti-folate receptor alpha antibody or an antigen-binding fragment thereof comprising the heavy chain amino acid sequence of SEQ ID NO: 15 and the light chain amino acid sequence of SEQ ID NO: 16;

[0206] (ii) D is eribulin;

[0207] (iii) L is a cleavable linker comprising Mal-(PEG)2-Val-Cit-pAB; and

[0208] (iv) p is an integer of about 4.

[0209] Therapeutic Uses

[0210] In various embodiments, disclosed herein are methods of treating a subject's disorder (e.g., a tumor disorder, e.g., a FRA-expressing cancer) using a disclosed anti-FRA ADC (e.g., an ADC comprising the six CDR amino acid sequences of MORAb-003, e.g., MORAb-202, the amino acid sequence being linked to a linker comprising Mal-(PEG)2-Val-Cit-pAB). The ADC can be administered alone or in combination (e.g., simultaneously or sequentially) with a second therapeutic agent (e.g., a corticosteroid, e.g., dexamethasone, prednisone, or methylprednisolone), and can be administered in any pharmaceutically acceptable formulation. In particular, the methods disclosed herein provide for the use of the disclosed anti-FRA ADC for treating a subject with a FRA-expressing cancer, wherein the dose of the ADC is based on the subject's body surface area (BSA). In some embodiments, a treatment method employing BSA administration can reduce the risk of interstitial lung disease (ILD) in a subject in need of treatment with an anti-FRA ADC. In some embodiments, the methods disclosed herein provide the use of the disclosed anti-FRA ADC for treating subjects who have previously received at least one systemic anti-cancer therapy (e.g., cytotoxic or targeted anti-cancer agents). In some embodiments, the methods disclosed herein provide the use of the disclosed anti-FRA ADC for treating subjects with metastatic cancers such as metastatic non-small cell lung cancer. In some embodiments, subjects with metastatic non-small cell lung cancer treated according to the disclosed methods have no genomic changes. In some embodiments, subjects with metastatic FRA-expressing cancers (e.g., metastatic non-small cell lung cancer) have at least one genomic change (e.g., at least one unknown or known genomic change). Examples of known genomic changes include, but are not limited to, genomic changes in any of the following genes: EGFR, ALK, PI3K, AKT, mTOR, RET, MET, BRAF, NTRK, ROS1, and any gene involved in the RAS-MAPK pathway. In some embodiments, subjects with metastatic FRA-expressing cancers have at least one known genomic change in at least one of any of the above genes. As used herein, "genomic changes" refer to any changes in the genome, including but not limited to somatic mutations, copy number variations, and gene fusions. In some embodiments, the methods disclosed herein provide for the use of the disclosed anti-FRA ADCs for treating a subject with a refractory cancer.As used herein, a "refractory cancer" is a cancer that has not responded to at least one prior therapy, ie, is non-responsive.In some embodiments, subjects with refractory cancers are unresponsive to targeted therapy, for example, treatments specifically targeting any of the following genes or variants thereof: epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), v-raf mouse sarcoma viral oncogene homolog 1 (BRAF), ret proto-oncogene (RET), MET proto-oncogene, receptor tyrosine kinase (MET), neurotrophic receptor tyrosine kinase (NTRK) and receptor tyrosine kinase (ROS1). As used herein, "targeted therapy" is a cancer therapy targeting certain genes and / or proteins involved in cancer cell growth and / or survival. As used herein, the term "variant" is used to refer to any naturally occurring variant of a gene, including but not limited to splice variants, allelic variants, isoforms and homologs (e.g., paralogs or orthologs). In contrast to genes comprising genomic changes, variants of genes are not associated or related to diseases or disorders such as cancer. In some embodiments, any of the above genes (or variants thereof) specifically targeted by targeted therapy may comprise at least one genomic change. For example, one targeted therapy might be specific for a mutation in NTRK1, while another targeted therapy might be specific for a mutation in NTRK2.

[0211] In some embodiments, subjects with refractory cancer are unresponsive to platinum-based treatments (e.g., platinum doublet chemotherapy) and / or immunotherapy-based treatments (e.g., immune checkpoint inhibitors, e.g., PD-1 inhibitors or PD-L1 inhibitors). In some embodiments, subjects with refractory cancer are unresponsive to treatment with platinum doublet chemotherapy and immune checkpoint inhibitors (e.g., PD-1 inhibitors or PD-L1 inhibitors), wherein the platinum doublet chemotherapy and immune checkpoint inhibitors are administered simultaneously or sequentially. In various embodiments, subjects with refractory cancer are unresponsive to no more than 3 previous systemic therapies, e.g., no more than 2 previous systemic therapies. In some embodiments, subjects with refractory cancer are unresponsive to no more than 1 previous chemotherapy.

[0212] In various embodiments, ADC therapeutic efficacy can be evaluated for toxicity and efficacy indicators and adjusted accordingly. Efficacy indicators include, but are not limited to, objective response rate (ORR). ORR can be measured after a given period of time after treatment, for example, 24 weeks after the start of treatment or thereafter. ORR can be determined based on tumor assessment according to RECIST, such as RECIST 1.1. As used herein, "RECIST" refers to solid tumor response evaluation criteria (RECIST), which is a set of standardized guidelines for measuring the degree of response of cancer patients to treatment (Therass et al. (2000) J Natl Cancer Inst. [National Cancer Institute Journal] 92: 205-16). As used herein, "RECIST 1.1" refers to RECIST version 1.1, in which the guidelines have been revised and updated relative to earlier versions of RECIST (Eisenhauer et al. (2009) Eur J Cancer. [European Journal of Cancer] 45: 228-47).

[0213] In some embodiments, the methods disclosed herein for treating FRA-expressing cancers comprise administering to a subject in need thereof a therapeutically effective amount of an ADC disclosed herein having formula (I), e.g., MORAb-202, wherein the ADC is administered to the subject at a dose based on the body surface area (BSA) of the subject.

[0214] In some embodiments, the methods disclosed herein for reducing the risk of ILD in a subject being treated for a FRA-expressing cancer comprise administering to the subject an ADC having formula (I) as disclosed herein, e.g., MORAb-202, wherein the ADC is administered to the subject at a dose based on the subject's BSA.

[0215] In some embodiments, ADC is administered at 8 mg to 50 mg / m2. 2 ) subject's BSA. In some embodiments, ADC is administered at a dose of 8 mg to 44 mg / m2 (m 2 ) subject's BSA. In some embodiments, ADC is administered at a dose of 11 mg to 44 mg / m2 (m 2 ) subject's BSA. In some embodiments, ADC is administered at a dose of 8 mg to 10 mg / m2 (m 2 ) dose of the subject's BSA. In some embodiments, the dose is 5-75 mg, 10-60 mg, 15-45 mg, or 20-40 mg, or 25-35 mg / m2 (m 2 ) subject BSA. In some embodiments, ADC is administered at 33 mg / m2 (m 2) subject's BSA. In some embodiments, ADC is administered at 25 mg / m2 (m 2 ) subject's BSA. In some embodiments, ADC is administered at 17 mg / m2 (m 2 ) dose of the subject's BSA. In some embodiments, ADC is administered at 15 mg / m2 (m 2 ) dose of the subject's BSA. In some embodiments, the ADC is administered at 10 mg / m2 (m 2 ) subject's BSA. In some embodiments, ADC is administered at 8 mg / m2 (m 2 ) BSA dose administration to a subject. Any of these doses may be administered once a week, once every two weeks, or once every three weeks.

[0216] BSA can be calculated using any acceptable method known in the art. Formulas for calculating the body surface area (BSA) of a subject include, for example, the Dubois and Dubois formula (or any variation thereof) (Dubois D, Dubois EF. (1916) Arch Intern Med. [Archives of Internal Medicine] 1916; 17: 863-871), the Mosteller formula (or any variation thereof) (Mosteller RD. (1987) N Engl J Med. [New England Journal of Medicine] 22; 317(17): 1098), or the Haycock formula (Haycock GB et al. (1978) J Pediatr. [Journal of Pediatrics] July; 93(1): 62-6). Exemplary formulas for calculating BSA are provided below:

[0217] (II) BSA(m 2 )=0.20247×Height(m) 0.725 ×Weight (kg) 0.425 (DuBois and DuBois);

[0218] (III)BSA(m 2 )=0.007184×Height(cm) 0.725 ×Weight (kg) 0.425 (variation of Dubois and Dubois);

[0219] (IV)BSA(m 2 ) = ([Height (cm) × Weight (kg)] / 3600) 1 / 2 (Mosteller);

[0220] or

[0221] (V)BSA(m2 )=0.024265×Height(cm) 0.3964 ×BW(kg) 0.5378 (Haycock).

[0222] In some embodiments, the actual dose of ADC to be administered to a subject can be calculated as follows:

[0223] (VI) Predetermined dose (mg / m 2 )×body surface area (BSA) (m 2 ) = actual dose (mg)

[0224] As used herein, "predetermined dose" refers to a dose selected from the dose range provided above to be administered to a subject (e.g., 8 mg to 50 mg). For example, ADC may be 33 mg / m 2 The predetermined dose is applied to a 1.8 square meter (m 2 ) of an exemplary BSA, as calculated by the above formula III using an assumed value of 160 cm height and 80 kg BW. In this particular example, according to the formula VI provided above, the amount or actual dose of ADC administered to the subject is 60.5 mg.

[0225] In some embodiments, the therapeutic dose can be recalculated on the first day of each treatment cycle using the subject's height measured at intake and the subject's weight measured on or before the first day of each treatment cycle (e.g., two days prior to the first day of each treatment cycle).

[0226] In some embodiments, the ADC is administered weekly, biweekly, every three weeks, monthly, or any time period therebetween. In some embodiments, the ADC is administered once every three weeks. In some embodiments, the ADC may be administered in a 21-day cycle. A treatment cycle of once every three weeks or a 21-day cycle may also be referred to as "Q3W". In some embodiments, the ADC is administered once every two weeks. In some embodiments, the ADC may be administered in a 14-day cycle. A treatment cycle of once every two weeks or a 14-day cycle may also be referred to as "Q2W". In some embodiments, the ADC is administered once a week. In some embodiments, the ADC may be administered in a 7-day cycle. A treatment cycle of once a week or a 7-day cycle may also be referred to as "QW".

[0227] In some embodiments, ADC is administered at 8 mg / m 2 Up to 50 mg / m 2 The BSA-dependent dose is administered once every three weeks. In some embodiments, the ADC is administered at 8 mg / m 2 Up to 50 mg / m 2 The BSA-dependent dose is administered once every two weeks. In some embodiments, the ADC is administered at 8 mg / m2 Up to 50 mg / m 2 The BSA-dependent dose is administered once a week. In some embodiments, the ADC is administered at 33 mg / m 2 The BSA-dependent dose is administered once every three weeks. In some embodiments, the ADC is administered at 33 mg / m 2 The BSA-dependent dose is administered once every two weeks. In some embodiments, the ADC is administered at 33 mg / m 2 The BSA-dependent dose is administered once a week. In some embodiments, the ADC is administered at 17 mg / m 2 The BSA-dependent dose is administered once every three weeks. In some embodiments, the ADC is administered at 17 mg / m 2 The BSA-dependent dose is administered once every two weeks. In some embodiments, the ADC is administered at 17 mg / m 2 The BSA-dependent dose is administered once a week. In some embodiments, the ADC is administered at 15 mg / m 2 The BSA-dependent dose is administered once every three weeks. In some embodiments, the ADC is administered at 15 mg / m 2 The BSA-dependent dose is administered once every two weeks. In some embodiments, the ADC is administered at 15 mg / m 2 The BSA-dependent dose is administered once a week. In some embodiments, the ADC is administered at 8 mg / m 2 Up to 10 mg / m 2 The BSA-dependent dose is administered once every three weeks. In some embodiments, the ADC is administered at 8 mg / m 2 Up to 10 mg / m 2 The BSA-dependent dose is administered once every two weeks. In some embodiments, the ADC is administered at 8 mg / m 2 Up to 10 mg / m 2 The BSA-dependent dose is administered once a week. In some embodiments, the ADC is administered at 10 mg / m 2 The BSA-dependent dose is administered once every three weeks. In some embodiments, the ADC is administered at 10 mg / m 2 The BSA-dependent dose is administered once every two weeks. In some embodiments, the ADC is administered at 10 mg / m 2 The BSA-dependent dose is administered once a week. In some embodiments, the ADC is administered at 8 mg / m 2 The BSA-dependent dose is administered once every three weeks. In some embodiments, the ADC is administered at 8 mg / m 2 The BSA-dependent dose is administered once every two weeks. In some embodiments, the ADC is administered at 8 mg / m 2 The BSA-dependent dose was administered once a week.

[0228] Without being bound by theory, the administration based on BSA disclosed herein can reduce exposure levels, for example, in a subject with higher body weight (BW) when using disclosed ADC, this can help reduce ILD risk.Without being bound by theory, compared with a subject with lower body weight, administration based on BW may cause the exposure of the subject of body weight in the upper quartile to be higher.Other exemplary dosing regimens that can reduce the total dose of the subject for treatment and exposure burden include administration using the BW with the maximum total dose upper limit or the ideal body weight (AIBW) of adjustment.In certain embodiments, administration based on BSA may be preferred because it is easy to use, more familiar to practitioners and reduces the possibility of producing administration errors.

[0229] In some embodiments, subjects treated with an anti-FRA ADC disclosed herein have a body weight value in the upper quartile of body weight. In some embodiments, subjects treated with an anti-FRA ADC disclosed herein have a body weight of at least 80 kg.

[0230] In some embodiments, compared to the treatment in which the ADC is administered at a dose based on body weight (BW), after the ADC is administered at a dose based on BSA, the risk of ILD in the subject treated with the anti-FRA ADC disclosed herein is reduced by at least 5%, at least 10%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, or at least 20%. In some embodiments, the contrast treatment is administered at a dose of 0.5 to 2 mg / kg of subject body weight (BW), for example, at a dose of 0.9 mg to 1.2 mg / kg of BW. For example, in some embodiments, the contrast treatment can be administered at a dose of 0.9 mg / kg of subject BW, which is comparable to a dose of 33 mg / m2 of subject BSA. In some embodiments, for a subject with an exemplary BW of 80 kg, administering the ADC at a dose based on BW of 0.9 mg / kg will result in an actual dose of 72 mg; in contrast, administering the ADC at a dose based on BW of 33 mg / m2 will result in an actual dose of 72 mg. 2 Administration of the ADC to the same subject at a BSA-based dose would result in an actual dose of 59.4 mg.

[0231] In some embodiments, the method disclosed herein may further include administering one or more additional therapeutic agents, such as one or more additional tumor agents. In some embodiments, additional agents include corticosteroids. Without being bound by theory, it is assumed that the potential mechanism of ILD may involve the FRA-independent interaction between the anti-FRA ADC disclosed herein and the lung macrophages in the pre-inflammatory lung microenvironment. "FRA-independent interaction" refers to the interaction between the anti-FRA ADC and the cell that is not caused by the recognition and binding of the FRA antigen on the cell, for example, binding. This interaction may lead to the induction of cytokines in the lung tissue of the subject. In addition, without being bound by theory, after the anti-FRA ADC is internalized into the macrophage, free eribulin can be released into the lung tissue of the subject. Without being bound by theory, due to the bystander effect of the ADC disclosed herein, free eribulin is released into the lung tissue and may cause tissue damage. Therefore, immune-mediated mechanisms may promote the development of ILD. Without being bound by theory, due to the immunomodulatory and anti-inflammatory effects of corticosteroids, the administration of corticosteroids can alleviate symptoms or completely prevent the development of ILD.

[0232] In certain embodiments, corticosteroid can be used prophylactically.As used herein, "prophylactic use" refers to applying treatment to a subject before a subject has or develops ILD symptoms, such as a corticosteroid.In certain embodiments, a corticosteroid is used simultaneously or sequentially with an ADC.In certain embodiments, a corticosteroid is used before or after the ADC is used.In certain embodiments, a corticosteroid is dexamethasone.In certain embodiments, a corticosteroid is prednisone.In certain embodiments, a corticosteroid is methylprednisolone.In certain embodiments, a corticosteroid (for example, dexamethasone, prednisone or methylprednisolone) can be used orally or intravenously.In certain embodiments, when a corticosteroid (for example dexamethasone or prednisone) is orally administered, it can be used with 1-10mg, for example 0.5-2mg, for example 2-5mg, for example 0.5mg, 1mg, 2mg or 4mg.In certain embodiments, dexamethasone is used with a dosage determined to be effective for treatment, for example, with 4mg of dexamethasone.In certain embodiments, dexamethasone is used at least once a day, for example, twice a day. In some embodiments, dexamethasone is administered for several days (e.g., 1, 2, 3, 4, 5 or more days) before or at the beginning of treatment with ADC. In some embodiments, dexamethasone is administered for at least three days at the beginning of treatment with ADC. In some embodiments, dexamethasone is administered orally. In some embodiments, prednisone is administered at a dose determined to be effective for treatment, for example, with 0.5 mg, 1 mg or 2 mg prednisone. In some embodiments, prednisone is administered with 0.5 mg prednisone. In some embodiments, prednisone is administered with 1 mg prednisone. In some embodiments, prednisone is administered with 2 mg prednisone. In some embodiments, prednisone is administered at least once a day. In some embodiments, prednisone is administered for several days (e.g., 10, 11, 12, 13, 14 or more days) before or at the beginning of treatment with ADC. In some embodiments, prednisone is administered for at least 14 days before treatment with ADC is started. In some embodiments, prednisone is administered orally. In some embodiments, when a corticosteroid (e.g., methylprednisolone) is administered intravenously, it can be administered in an amount of 300-1200 mg (e.g., 400-1100 mg, e.g., 500-1000 mg, e.g., 500 mg, 750 mg, or 1000 mg). In some embodiments, methylprednisolone is administered in an amount of 30-130 mg, e.g., 40-125 mg. In some embodiments, methylprednisolone is administered in an amount of 1 mg / kg subject body weight. In some embodiments, methylprednisolone is administered in an amount of 2 mg / kg subject body weight. In some embodiments, methylprednisolone is administered intravenously. In some embodiments, methylprednisolone is administered orally.In some embodiments, when methylprednisolone is orally administered, it can be administered in an amount of 5-100mg, such as 5-90mg, such as 5-80mg, such as 10-80mg, such as 10mg-70mg, such as 10-60mg. In some embodiments, methylprednisolone is orally administered with 0.5-1.5mg / kg subject weight. In some embodiments, methylprednisolone is orally administered with 0.5mg / kg subject weight. In some embodiments, methylprednisolone is orally administered with 1mg / kg subject weight. In some embodiments, methylprednisolone is orally administered with 1.5mg / kg subject weight. In some embodiments, methylprednisolone is administered at least once a day. In some embodiments, before or at the beginning of treatment with ADC, methylprednisolone is administered for several days (e.g., 1, 2, 3, 4, 5 or more days). In some embodiments, methylprednisolone is administered for at least three days before treatment with ADC begins.

[0233] The methods disclosed herein can be applied to human subjects in need of treatment, e.g., subjects suffering from cancer, e.g., FRA-expressing cancer. In some embodiments, the methods disclosed herein can be applied to non-human mammals suffering from FRA-expressing cancer for veterinary purposes or as an animal model of human disease. In the latter, such animal models can be used to evaluate the therapeutic efficacy of the disclosed methods (e.g., testing doses and administration schedules).

[0234] The ADC disclosed herein can be administered to a subject by any suitable route of administration to produce a therapeutic effect. In some embodiments, the ADC is administered intravenously to a subject.

[0235] In some embodiments, the disclosure features a method for treating a FRA-expressing cancer. The method can be used to treat any human or non-human mammalian subject suffering from a FRA-expressing cancer, for example, those subjects for whom the destruction of tubulin provides a therapeutic benefit. Methods for identifying subjects suffering from FRA-expressing cancer are known in the art and can be used to identify subjects suitable for treatment with the disclosed ADC. The FRA-expressing cancer can be a primary or metastatic FRA-expressing cancer, or a FRA-expressing cancer resistant to platinum-based therapy, for example, a platinum-resistant cancer. Non-limiting examples of FRA-expressing cancers include gastric cancer, ovarian cancer (e.g., serous ovarian cancer, clear cell ovarian cancer, or platinum-resistant ovarian cancer), lung cancer (e.g., non-small cell lung cancer, e.g., metastatic non-small cell lung cancer), lung carcinoid, colorectal cancer, breast cancer (e.g., triple-negative breast cancer or hormone receptor (HR) positive and low HER2 breast cancer), endometrial cancer (e.g., serous endometrial cancer), peritoneal cancer (e.g., primary peritoneal cancer), fallopian tube cancer, pancreatic cancer, kidney cancer (e.g., renal cell carcinoma), cervical cancer, esophageal cancer, and osteosarcoma. In some embodiments, the FRA-expressing cancer is ovarian cancer, e.g., platinum-resistant ovarian cancer. In some embodiments, the FRA-expressing cancer is breast cancer, e.g., triple-negative breast cancer (TNBC). In some embodiments, the FRA-expressing cancer is non-small cell lung cancer (NSCLC), e.g., metastatic non-small cell lung cancer. In some embodiments, the FRA-expressing cancer is endometrial cancer.

[0236] In certain embodiments, the present disclosure is characterized in that a method for reducing the ILD risk of a subject suffering from FRA expression type cancer is provided, wherein the subject needs treatment. For the purpose of reducing ILD risk, the method can be used for any person or non-human mammal subject suffering from FRA expression type cancer. FRA expression type cancer can be primary or metastatic FRA expression type cancer, or FRA expression type cancer resistant to platinum-based therapy, for example, platinum-resistant cancer. The non-limiting examples of FRA expression type cancer include gastric cancer, ovarian cancer (for example, serous ovarian cancer, clear cell ovarian cancer or platinum-resistant ovarian cancer), lung cancer (for example, non-small cell lung cancer, for example, metastatic non-small cell lung cancer), lung carcinoid, colorectal cancer, breast cancer (for example, triple-negative breast cancer or hormone receptor (HR) positive and low HER2 breast cancer), endometrial cancer (for example, serous endometrial cancer), peritoneal cancer (for example, primary peritoneal cancer), fallopian tube cancer, pancreatic cancer, kidney cancer (for example, renal cell carcinoma), cervical cancer, esophageal cancer and osteosarcoma. In some embodiments, the FRA-expressing cancer is ovarian cancer, e.g., platinum-resistant ovarian cancer. In some embodiments, the FRA-expressing cancer is breast cancer, e.g., triple-negative breast cancer (TNBC). In some embodiments, the FRA-expressing cancer is non-small cell lung cancer (NSCLC), e.g., metastatic non-small cell lung cancer. In some embodiments, the FRA-expressing cancer is endometrial cancer.

[0237] In various embodiments, the methods disclosed herein, e.g., using BSA-based dosing of an anti-FRA ADC such as MORAb-202, e.g., at 8 to 50 mg / m 2 The BSA-dependent dose of 100 mg / ml is used to treat ovarian cancer, platinum-resistant ovarian cancer, breast cancer, triple-negative breast cancer, non-small cell lung cancer, or endometrial cancer. In some embodiments, the methods disclosed herein are used to treat primary peritoneal cancer or fallopian tube cancer. In some embodiments, 33 mg / ml of 10 ... 2 BSA-dependent doses are used to treat platinum-resistant ovarian cancer (PROC). In some embodiments, 25 mg / m2 administered Q3W 2 BSA-dependent doses are used to treat PROC. In some embodiments, 17 mg / m 2 BSA-dependent doses are used to treat PROC. In some embodiments, 15 mg / m 2 BSA-dependent doses are used to treat PROC. In some embodiments, 8 mg / m 2 Up to 10 mg / m 2In some embodiments, the PROC is serous ovarian cancer. In some embodiments, the PROC is high-grade serous ovarian cancer. In some embodiments, 33 mg / m 2 Q3W BSA-based dosing is used to treat primary peritoneal cancer. In some embodiments, 25 mg / m 2 BSA-based dosing Q3W is used to treat primary peritoneal cancer. In some embodiments, 17 mg / m 2 BSA-based dosing Q3W is used to treat primary peritoneal cancer. In some embodiments, 15 mg / m 2 Q2W BSA-based dosing is used to treat primary peritoneal cancer. In some embodiments, 8 mg / m 2 Up to 10 mg / m 2 QW based on BSA dose is used to treat primary peritoneal cancer. In some embodiments, 33 mg / m 2 BSA-based dosing Q3W is used to treat fallopian tube cancer. In some embodiments, 25 mg / m 2 BSA-based dosing Q3W is used to treat fallopian tube cancer. In some embodiments, 17 mg / m 2 BSA-based dosing Q3W is used to treat fallopian tube cancer. In some embodiments, 15 mg / m 2 Q2W BSA-based dosing is used to treat fallopian tube cancer. In some embodiments, 8 mg / m 2 Up to 10 mg / m 2 BSA-based dosing of QW is used to treat fallopian tube cancer. In some embodiments, the subject treated according to the methods disclosed herein has a cancer that recurred within six months of receiving a platinum-based therapy.

[0238] In some embodiments, subjects who experience a treatment-related adverse event (TRAE) may subsequently be treated with a reduced dose level of MORAb-202. In some embodiments, subjects who are administered 33 mg / m 2 Subjects who received a BSA-based dose and experienced a TRAE could then be administered 25 mg / m 2 In some embodiments, 25 mg / m 2 Subjects who received a BSA-based dose and experienced a TRAE could subsequently be administered 17 mg / m 2 In some embodiments, 25 mg / m 2 Subjects who received a BSA-based dose and experienced a TRAE could then be administered 15 mg / m 2 In some embodiments, 25 mg / m 2Subjects who received a BSA-based dose and experienced a TRAE could then be administered 8 mg / m 2 Up to 10 mg / m 2 In some embodiments, 15 mg / m 2 Subjects who received a BSA-based dose and experienced a TRAE could then be administered 8 mg / m 2 Up to 10 mg / m 2 In some embodiments, TRAE is evaluated and assigned a specific grade level according to NCI CTCAEv5. As used herein, NCI CTCAE v5 refers to the 5th edition of the National Cancer Institute Common Terminology Criteria forAdverse Events, which is a descriptive term for adverse event reporting, wherein a grading (severity) scale is provided for each adverse event term. In some embodiments, TRAE is a transfusion-related reaction of grade 1 or higher (e.g., grade 2, 3, or 4). In some embodiments, TRAE is an interstitial lung disease (ILD) or pneumonia of grade 1 or higher (e.g., grade 2, 3, or 4). In some embodiments, TRAE is a reduction in neutrophil counts of grade 3 or grade 4 or equal to or less than 1000 cells / μl in a subject's blood sample. In some embodiments, TRAE is a febrile neutropenia of grade 3 or higher. In some embodiments, TRAE is a reduction in platelet counts of grade 2 or higher or equal to or less than 75,000 cells / μl in a subject's blood sample. In some embodiments, a TRAE is any symptomatic or asymptomatic laboratory result of grade 3 or higher. In some embodiments, a TRAE is any non-hematologic toxicity of grade 3 or higher.

[0239] In some embodiments, the methods disclosed herein, e.g., using BSA-based dosing of an anti-FRA ADC such as MORAb-202, e.g., at 8 to 50 mg / m 2 The BSA-dependent dose of 1 mg / kg / day reduced the risk of ILD.

[0240] Prior to initiating treatment, subjects may be evaluated by certain clinical criteria to identify those subjects who may be at high risk for severe respiratory complications. If it is determined that the subject may be at high risk for severe respiratory complications, the subject may be excluded from treatment according to the methods disclosed herein. In some embodiments, subjects treated according to the aforementioned methods are evaluated by pulmonary function testing (PFT) prior to treatment. In some embodiments, subjects evaluated by PFT and subsequently treated do not have one or more of the following results: FEV1 / FVC ratio less than 0.7, FEV1 (forced expiratory volume in the first second) less than 80%, FVC (forced vital capacity) less than 80%, or DLCO (diffusing capacity of the lungs for carbon monoxide) less than 80%. In certain embodiments, the subject treated according to the aforementioned methods does not have one or more of the following when treatment begins: interstitial lung disease (ILD) and / or pneumonia, ILD and / or pneumonia history, clinically significant lung-specific disease, pleural effusion, pericardial effusion, previous lung resection, chest radiotherapy history in the past 2 years, autoimmune disorders with lung involvement, connective tissue disorders with lung involvement or inflammatory disorders with lung involvement. Exemplary clinically significant lung-specific disease includes but is not limited to any potential lung disorder (such as pulmonary embolism), asthma, chronic obstructive pulmonary disease (COPD), restrictive lung disease or any other lung-specific inflammatory disease or illness.

[0241] In some embodiments, the subject treated according to the aforementioned method does not have one or more of the following: a history of more than three previous therapies for FRA-expressing cancer, a high neutrophil-to-lymphocyte ratio, or a serum albumin level of less than 3 g / dL at the start of treatment. As used herein, "high neutrophil-to-lymphocyte ratio" refers to the ratio of neutrophils to lymphocytes in a subject's blood sample or "neutrophil-to-lymphocyte ratio" (NLR), which is higher than the average NLR of a comparison group (e.g., a group of adults in the general population or a group of subjects with FRA-expressing cancer). In some embodiments, high NLR can be at least 3, at least 4, at least 5, at least 6, at least 7, at least 8 or at least 9. NLR can be calculated using any method known in the art. For example, NLR can be calculated by dividing the number of neutrophils by the number of lymphocytes. The number of neutrophils and the number of lymphocytes can be measured from a peripheral blood sample of the subject. NLR can be calculated using absolute cell counts of neutrophils and / or lymphocytes, or using relative percentages of neutrophils and / or lymphocytes.

[0242] Pharmaceutical compositions and formulations

[0243] The ADC for implementing the aforementioned method can be formulated into a pharmaceutical composition suitable for application to a subject, such as a human subject. In some embodiments, the pharmaceutical composition comprises an ADC and a pharmaceutically acceptable carrier suitable for the desired delivery method. Suitable carriers include any material that, when combined with the ADC disclosed herein, allows the ADC to retain its anti-tumor function and generally does not react with the subject's immune system. Pharmaceutically acceptable carriers may include any and all solvents, dispersion media, coating agents, antibacterial and antifungal agents, isotonic agents, and absorption delay agents that are physiologically compatible. Examples of pharmaceutically acceptable carriers include one or more of water, saline, phosphate-buffered saline, dextrose, glycerol, ethanol, mesylate, and the like, and combinations thereof. In some embodiments, the formulation includes one or more isotonic agents, such as sugars, polyols such as mannitol, sorbitol, or sodium chloride. Pharmaceutically acceptable carriers may include a very small amount of auxiliary substances, such as wetting agents or emulsifiers, preservatives, or buffers, which enhance the shelf life or effectiveness of ADC.

[0244] The pharmaceutical compositions described herein can be in various forms. These forms include, for example, liquid, semisolid and solid dosage forms, such as liquid solutions (e.g., injectable solutions and infusible solutions), dispersions or suspensions, tablets, pills, powders, liposomes and suppositories. The preferred form depends on the intended mode of administration and therapeutic application.

[0245] The pharmaceutical composition is soluble and can be administered via any route capable of delivering the composition to the tumor site. Potentially effective routes of administration include but are not limited to intravenous, parenteral, intraperitoneal, intramuscular, intratumoral, intradermal, intraorgan, orthotopic, etc. The pharmaceutical composition can be lyophilized and stored in a sterile powder form preferably under vacuum, and then reconstituted in antibacterial water (containing, for example, benzyl alcohol preservative) or sterile water before injection. Administration can be systemic or local. The pharmaceutical composition may include ADC or a pharmaceutically acceptable salt thereof (e.g., mesylate). The pharmaceutical composition may further include a corticosteroid, such as dexamethasone, prednisone or methylprednisolone. Alternatively, in some embodiments, a corticosteroid may be provided in a separate package.

[0246] In various embodiments, kits for therapeutic applications described herein are within the scope of the present disclosure. Such kits may include an ADC disclosed herein and a carrier, package, or container. The carrier, package, or container may be partitioned to accommodate one or more containers, such as vials, test tubes, etc., each of which contains the following: one of the independent elements to be used in the methods disclosed herein and / or a label or insert containing instructions for use, such as the uses described herein. The carrier, package, or container may also include a compartment for a corticosteroid.

[0247] The kit may further comprise one or more other containers associated therewith containing materials desirable from a commercial and user standpoint, including buffers, diluents, filters, needles, syringes; carriers, packages, container, vials and / or sleeve labels listing the contents and / or instructions for use; and a package insert with instructions for use.

[0248] The label may be present on or in the container to indicate that the composition is used for a specific therapy or non-therapeutic application, such as prognosis, prevention, diagnosis or laboratory application. The label may also indicate instructions for in vivo or in vitro use (such as the use described herein). Instructions and / or other information may also be included on one or more inserts or one or more labels included in or on the kit. The label may be on or associated with the container. When letters, numbers or other characters forming the label are molded or etched into the container itself, the label may be on the container. When the label is present in a receptacle or carrier that also holds the container, the label may be associated with the container, for example, in the form of a package insert. The label may indicate that the composition is used for diagnosis or treatment of a condition of a cancer as described herein.

[0249] It will be apparent to those skilled in the art that the methods of the invention described herein are evident and other suitable modifications and adaptations thereof may be made using suitable equivalents without departing from the scope of the invention or embodiments disclosed herein. Having now described the invention in detail, they will be more clearly understood by reference to the following examples, which are included for illustrative purposes only and are not intended to be limiting.

[0250] Example 1

[0251] 1.1 Dose-Response Relationship of ORR in PROC Subjects

[0252] MORAb-202 was administered to subjects (N=58) with platinum-resistant ovarian cancer (PROC) at a weight-based (BW) dose range of 0.3 to 1.2 mg / kg. All doses were administered Q3W. A dose-response assessment was performed to calculate the relationship between dose and objective response rate (ORR) within this dose range.

[0253] 1.2 Dose-response relationship of ILD across tumor types

[0254] MORAb-202 was administered to subjects (N=82) with PROC, endometrial cancer (EC), triple-negative breast cancer (TNBC), and non-small cell lung cancer (NSCLC) within a dose range of 0.3 to 1.2 mg / kg based on body weight (BW). All doses were administered Q3W. Dose response assessments were performed to calculate the relationship between dose and ILD rate within this dose range.

[0255] 1.2.1 Results

[0256] Clinical pharmacology evaluation was performed to evaluate the dose relationship between MORAb-202 and objective response rate (ORR) or ILD. The dose response relationship was calculated using logistic regression analysis. The results of these analyses are listed in Tables 11 and 12 below.

[0257] Table 11. Dose response of ORR in PROC

[0258]

[0259] Table 12. Dose response of ILD across tumor types

[0260]

[0261] In subjects with PROC, there was a dose-response relationship between MORAb-202 and ORR in the dose range of 0.68 to 1.2 mg / kg. Similarly, in subjects across tumor types (PROC, EC, TNBC, NSCLC), there was a dose-response relationship between MORAb-202 and ILD in the dose range of 0.68 to 1.2 mg / kg. The highest dose of 1.2 mg / kg had the highest ORR in subjects with PROC and the highest ILD rate in subjects across tumor types. The next lower dose of 0.9 mg / kg corresponds to a lower ORR and ILD rate in the two subject groups. Given that the dose of 0.9 mg / kg has a lower ILD rate while still providing a therapeutically meaningful benefit (i.e., ORR>30%), it was selected as the starting dose for subsequent simulation experiments.

[0262] 1.2.2 Exposure-Response (ER) Analysis of ORR in PROC Subjects

[0263] ER efficacy (ORR) was analyzed in PROC subjects (N=58) across the dose range of 0.3 to 1.2 mg / kg Q3W. Twenty-one subjects had a PR (partial response) and 2 subjects had a CR (complete response) in PROC across the dose range, for an ORR of 39.7% (23 / 58). Exposure (AUC) was the only significant predictor of the probability of objective response in multivariate analysis (e.g. Figure 1Age, weight, non-advanced serous OC (vs. advanced serous OC), ECOG-PS (1 vs. 0), and expansion (vs. dose escalation) were not significant predictors of objective response (OR). Given the linear PK and unsaturated OR within the current dose range, higher doses above 1.2 mg / kg Q3W are expected to result in higher OR probabilities. Based on the results of the ER analysis, clinically meaningful efficacy is expected within the dose range of 0.68 to 1.2 mg / kg. However, as described in Section 1.2.3, overlapping AUC dependencies on ILD were observed.

[0264] 1.2.3 PROC and Exposure-Response (ER) Analysis of ILD in Subjects Across All Tumor Types

[0265] ER analysis of ILD was performed using data from PROC subjects at a dose range of 0.3 to 1.2 mg / kg Q3W and subjects across tumor types (PROC, EC, TNBC, and NSCLC) at a dose range of 0.9 to 1.2 mg / kg Q3W (total N=96). Across subject groups and dose ranges, forty-eight subjects had ILD confirmed by expert review, with an ILD incidence of 50% (48 / 96). AUC and age were significant predictors in multivariate analysis, with both higher AUC and higher age predicting a higher probability of ILD. Weight, albumin, ECOG-PS (1 vs. 0), study, and tumor type (OC vs. other) were not significant predictors. The probability of ILD by AUC was predicted at the median age (60 years) and plotted together with the observed ILD rate for each exposure quartile (as shown in Figure 2A). Figure 2 shown).

[0266] 1.3 Dosage regimen simulation

[0267] Different dosing regimens were simulated to select a dose of MORAb-202 that would minimize the ILD rate while maintaining a high ORR. Stochastic simulations were performed using the population pharmacokinetic (PPK) model of MORAb-202 shown in Table 13 to predict the AUC and C of different dosing regimens. 最大 . MORAb-202 exposure was found to be dose proportional, and PK was described by a 2-compartment model with zero-order IV infusion and first-order clearance. BW and serum albumin were significant covariates for CL (total clearance) and BW was a significant covariate for volume of distribution. Five dosing regimens were simulated: 1) a steady-state dose of 63 mg; 2) a BW-based dose of 0.9 mg / kg; 3) a BW-based dose of 0.9 mg / kg with a maximum total dose capped at 70 mg; 4) a dose based on adjusted ideal body weight (AIBW) of 1.0 mg / kg; and 5) a 33 mg / m 2The BSA-based dose was 0.9 mg / kg (equivalent to a BW-based dose of 0.9 mg / kg). All dosing regimens were simulated in the Q3W treatment cycle.

[0268] Table 13. MORAb-202 parameter estimates for the final PPK model

[0269]

[0270] Eta reduction (%): ETA_CL: 2.3%; ETA_V1: 7.7%; ETA_V2: 20.6%; EPS reduction (%): 9.2%

[0271] %RSE = relative standard error of the estimate

[0272] 1.3.1 Results

[0273] The simulation results are as follows Figure 3 As shown. Dosing based on the plateau dose is expected to result in a 27% decrease in the median AUC for subjects in the highest BW quartile compared to subjects in the lowest BW quartile. BW-based dosing is expected to result in a 28% increase in the median AUC for subjects in the highest BW quartile compared to subjects in the lowest BW quartile. Dosing regimens (e.g., limiting the BW-based dose to 70 mg, using AIBW-based dosing, or using BSA-based dosing) are expected to produce an AUC that is independent of body weight, thereby reducing MORAb-202 exposure levels in subjects with higher body weight. Table 6 provides AUC, C for the clinically evaluated BW-based dose ranges (described in Sections 1.1 and 1.2) and equivalent BSA-based doses. 最大 , ORR, and ILD prediction. The estimated dose based on BSA is 33 mg / m 2 This would provide similar median exposure levels to the BW-based dose of 0.9 mg / kg. The BSA-based dose of 25 mg / m 2 This may provide similar median exposure levels to the BW-based dose of 0.68 mg / kg while still providing potential therapeutic benefit with a predicted ORR of approximately 24%.

[0274] Table 14. Predicted AUC, C of MORAb-202 at weight-based doses and equivalent body surface area-based doses 最大 , ORR and ILD

[0275]

[0276]

[0277] AUC = Area Under the Curve; C 最大=maximum concentration of MORAb-202 in blood after administration; ORR=objective response rate; ILD=interstitial lung disease; PI=prediction interval.

[0278] Values ​​based on simulations (N=1000 / dose in each dosing regimen).

[0279] 1.4 Comparison of BSA-based and BW-based dosing

[0280] Based on clinical pharmacology evaluation of the BW-based doses evaluated (described in Sections 1.1 and 1.2) and simulation results of different dosing schedules (described in Section 1.3), 33 mg / m 2 A BSA-based dose of 33 mg / m2 (Q3W) was selected based on the results of simulation analyses that showed that this dose would reduce ILD rates while maintaining a therapeutic benefit (i.e., ORR>30%). Additional simulations were performed to compare a BSA-based dose of 33 mg / m2 2 Predicted clinical outcomes compared to a BW-based dose of 0.9 mg / kg. All simulation comparisons were based on a Q3W treatment cycle.

[0281] 1.41. Results

[0282] At a BSA-based dose of 33 mg / m 2 The predicted median concentrations of MORAb-202 over time were found to be similar to the median concentrations of MORAb-202 over the same time period at a BW-based dose of 0.9 mg / kg ( Figure 4 ). AUC and C across weight quartiles 最大 , ORR, and ILD predictions were also similar for both dosing regimens (Table 15). Of note, the BSA-based 33 mg / m 2 The exposure level of MORAb-202 is expected to be more evenly modulated in subjects across BW quartiles. The BSA-based dosing approach maintains similar exposure to the BW-based dosing approach in subjects in the lower BW quartiles while reducing exposure in subjects in the highest BW quartile. Thus, the BSA-based dose of 33 mg / m 2 This was predicted to reduce the ILD rate by 18.4% in subjects in the highest BW quartile.

[0283]

[0284] Example 2

[0285] 2.1 Research details

[0286] A multicenter, open-label Phase 1 / 2 trial evaluating the safety, tolerability, and efficacy of MORAb-202, a folate receptor alpha (FRA)-targeted antibody-drug conjugate, will be conducted in subjects with selected tumor types. The Phase 1 / 2 study is expected to last approximately 2 years with an enrollment period of approximately 15 months.

[0287] 2.1.1 Objectives

[0288] The trial will be divided into two parts: a dose escalation part and a dose confirmation part.

[0289] 2.1.1.1 Main objectives

[0290] The primary objectives of the dose-escalation portion are to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of MORAb-202 in subjects with selected tumor types (ovarian cancer (OC), endometrial cancer (EC), non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC)).

[0291] The primary objectives of the dose confirmation portion are to further evaluate the safety and tolerability of MORAb-202 and to assess the preliminary efficacy as measured by the objective response rate (ORR) of MORAb-202 in OC and EC subjects at the selected dose.

[0292] 2.1.1.2 Secondary Objectives

[0293] Secondary objectives of the trial are to: (i) assess duration of response (DOR), disease control rate (DCR), and clinical benefit rate (CBR); (ii) assess progression-free survival (PFS) and overall survival (OS); (iii) determine the pharmacokinetic (PK) profiles of MORAb-202, total antibody, and eribulin released in serum or plasma; and (iv) evaluate the relationship between folate receptor alpha (FRA) expression levels and clinical outcome measures to support the identification of appropriate FRA cutoff points.

[0294] 2.1.1.3 Exploratory Objectives

[0295] The exploratory objectives of this trial are to: (i) assess oxygen saturation using pulse oximetry to detect and monitor interstitial lung disease (ILD); (ii) explore potential blood and tumor pharmacodynamic (PD) biomarkers (e.g., soluble FRA) and correlate with clinical outcome measures including PK, pharmacogenomic (PG), safety, and efficacy; (iii) investigate the effect of MORAb-202 on ventricular repolarization (dose-escalation portion only); (iv) evaluate the relationship between prior lines of therapy and clinical outcome measures (OC only); and (v) evaluate the utility of a computer-based algorithm to objectively detect lung parenchymal patterns consistent with ILD (e.g., honeycombing, ground-glass opacity) on high-resolution lung CT images to detect potential predisposing pathology, changes indicative of early ILD, and changes associated with resolution of ILD.

[0296] 2.2 Study design

[0297] MORAb-202 will be administered as an intravenous (IV) infusion every 3 weeks (21-day cycle). Treatment will be discontinued upon intolerable toxicity, disease progression, or subject withdrawal for any reason.

[0298] 2.2.1 Analysis of folate receptor α (FRA) expression

[0299] All selected tumor types will be enrolled regardless of tumor FRA expression level. However, FRA expression levels will be determined prospectively to analyze the correlation of FRA levels with efficacy outcomes. Tumor samples for evaluation of FRA expression levels are required for entry into the study (as described in the inclusion criteria in Section 2.2.5). After the dose confirmation portion is completed, an analysis will be performed to determine a clinically meaningful FRA cut point.

[0300] 2.2.2 Dose escalation

[0301] For the dose escalation part, three doses are planned: 0.9, 1.2, and 1.6 mg / kg. Up to 6 subjects will be accrued at each dose level using a rolling 6 design. Subjects will have any of the following 4 tumor types: OC, EC, NSCLC, and TNBC.

[0302] Additional OC subjects will be accrued to reach approximately 10 such subjects at each dose level. These additional subjects will not be used for dose escalation decisions, but their safety and efficacy data will contribute to the determination of the RP2D.

[0303] If necessary, additional subjects may be accrued at the selected dose level for RP2D determination.

[0304] 2.2.2.1 Rolling 6 Design

[0305] Dose levels are assigned based on the number of subjects currently enrolled in the cohort, the number of dose-limiting toxicities (DLTs) observed, and the number of subjects at risk of developing DLTs (i.e., subjects enrolled but not yet evaluated for toxicity). The dose assignment rules are shown in the dose decision table for the rolling 6 design.

[0306] If the escalation or downgrading rules have not been met by the time the next available subject is enrolled in the study, the subject who is not evaluable for DLT will be replaced with the next available subject.

[0307] 2.2.2.2 Selection of RP2D

[0308] The RP2D will be determined based on a comprehensive evaluation of safety, efficacy, PK, and PD data. The determination of DLT and RP2D will be agreed upon between the sponsor and the investigator.

[0309] Toxicity will be monitored continuously during the dose confirmation portion of the study (described in Section 2.2.3) with the Independent Data Monitoring Committee (IDMC). At any time, if there is concern about toxicity, the IDMC, investigators, and sponsor will re-evaluate the MORAb-202 dose and consider appropriate action.

[0310] 2.2.3 Dose confirmation

[0311] The dose confirmation portion will evaluate the safety and preliminary efficacy of MORAb-202 in OC and EC subjects at the selected dose level. An overview of the study design is as follows Figure 5 shown.

[0312] The dose confirmation portion will have approximately 30 subjects in the 4 study treatment cohorts. If ≥2 ≥Grade 3 ILD / pneumonitis (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE v5.0]) events are observed at any time, the sponsor will pause enrollment pending IDMC review. The initial cohort will enroll 6 subjects at 25 mg / m2 of MORAb-202.

[0313] If all 6 subjects in the 25 mg / m2 cohort have no ≥3 ILD events observed after ILD assessment (clinical and radiological) at least 6 weeks after C1D1 (Cycle 1 Day 1), 6 subjects will be enrolled in the second cohort at 33 mg / m2. If all 6 subjects in the 33 mg / m2 cohort have <2 ≥3 ILD events observed after ILD assessment (clinical and radiological) at least 6 weeks after C1D1, the study will continue with 2 cohorts, 25 mg / m2 and 33 mg / m2, with 9 subjects randomized to each cohort.

[0314] If 1 ≥ Grade 3 ILD event occurs after administration to all 6 subjects in the 25mg / m2 cohort, the cohort will be expanded to enroll an additional 9 subjects (a total of 15). After 6 weeks of observation of all 15 subjects to evaluate ILD, if there are <2 ≥ Grade 3 ILD events, 6 subjects will be opened for enrollment at the 33mg / m2 dose level. If there are <2 ≥ Grade 3 ILD events in these 6 subjects, the cohort will be expanded to enroll a total of 15 subjects.

[0315] The data will be analyzed to determine an acceptable regimen or regimens for further study. The incidence and severity of ILD in the cohort will be observed during the study. Efficacy will be assessed by ORR at week 24.

[0316] The dosing regimen for this study was based on body surface area (BSA) dosing. The dose levels used in this portion of the study have been matched to body weight doses of 0.9 mg / kg and 0.68 mg / kg, with BSA doses of 33 mg / m2 and 25 mg / m2, respectively. Predictions from the MORAb-202 population PK model (as described in Example 1) were used to confirm BSA dose equivalence. This revised dosing regimen has been implemented in the dose confirmation portion of this study because of the potential for reduced ILD risk in higher body weight subjects when using doses within the MORAb-202 therapeutic index range.

[0317] 2.2.3.1 Study period

[0318] There will be 3 periods for each subject: a pre-treatment period, a treatment period, and a follow-up period.

[0319] Pretreatment Period: First 28 to Day -1, CT / Magnetic Resonance Imaging (MRI) scans must be performed within 28 days prior to study drug administration. Unless otherwise specified, all clinical and laboratory test results used to determine eligibility must be performed within 7 days prior to study drug administration.

[0320] Treatment Period: MORAb-202 will be administered intravenously every 3 weeks (21-day cycles), also known as Q3W. Subjects may continue to receive treatment until intolerable toxicity, disease progression, or subject withdrawal for any reason.

[0321] Follow-up Period: After discontinuation of study drug, see the "Duration of Treatment" section for discontinuation criteria, a discontinuation visit will be conducted, and all subjects will be followed up for survival every 12 weeks thereafter for up to 3 years. Subjects who discontinue study treatment for reasons other than disease progression (PD) should have tumor assessments from the date of the last assessment according to the assessment schedule until disease progression is documented or the subject starts another anticancer therapy, whichever occurs first, unless the study is terminated or the subject withdraws consent for follow-up. Data on subsequent anticancer therapy will be collected. If a subject discontinues study treatment due to ILD, or ILD is ongoing at the time of treatment cessation (e.g., after PD or adverse event [AE] occurrence), chest CT scans should continue (per protocol ILD assessment time point) until ILD resolves or stabilizes (no worsening on 3 consecutive chest CT scans).

[0322] All subjects will be followed up for 3 years of survival unless the subject withdraws consent or the sponsor chooses to discontinue survival follow-up after completion of the primary study analysis.

[0323] End of Study: End of study will be defined as the time when the last subject / last visit or sponsor terminates the study. Earlier data cutoffs may occur for the preparation of the primary clinical study report.

[0324] 2.2.4 Number of subjects

[0325] Approximately 36 subjects will be enrolled in the dose escalation portion of the study and approximately 30 subjects will be enrolled in the dose confirmation portion of the study.

[0326] 2.2.5 Inclusion criteria

[0327] Subjects must meet all of the following criteria to be included in this study:

[0328] 1. Aged ≥ 18 years;

[0329] 2. For dose escalation:

[0330] ●Female (TNBC, EC, and OC) or male / female (NSCLC adenocarcinoma). Subjects with the following disease characteristics:

[0331] ○ TNBC: Histologically confirmed metastatic TNBC (i.e., estrogen receptor [ER]-negative / progesterone receptor-negative / human epidermal growth factor receptor 2 [HER2]-negative (defined as IHC <2+ or fluorescence in situ hybridization [FISH]-negative) breast cancer). Prior treatment with at least one line of systemic anticancer therapy (cytotoxic or targeted anticancer drugs) in the metastatic setting.

[0332] ○ NSCLC adenocarcinoma: Histologically or cytologically confirmed metastatic NSCLC adenocarcinoma: Subjects who have failed previous treatment for metastatic disease and are not suitable for epidermal growth factor receptor (EGFR), ALK, BRAF, or ROS1 targeted therapies or have failed these targeted therapies and there is no alternative standard treatment.

[0333] ○EC: Histologically confirmed advanced, recurrent or metastatic EC. Relapse or failure of at least one platinum-based regimen or one immunotherapy-based regimen.

[0334] ○ Ovarian or primary peritoneal or fallopian tube cancer: Histologically confirmed high-grade serous epithelial OC or primary peritoneal or fallopian tube cancer. Subjects must have:

[0335] Platinum-resistant disease (defined as progression within 6 months of the last dose of at least 4 cycles of the last platinum-containing chemotherapy regimen)

[0336] ■Received up to 4 lines of systemic therapy after development of platinum resistance.

[0337] For dose confirmation:

[0338] Ovarian or primary peritoneal or fallopian tube cancer:

[0339] ○ Platinum-resistant disease is defined as:

[0340] ■For participants who received 1 line of platinum-based therapy: RECIST v1.1 progression >1 month and ≤6 months after the last dose of the first platinum-based chemotherapy regimen (of at least 4 cycles)

[0341] ■For participants who received 2-3 lines of platinum-containing therapy: RECIST v1.1 progression during or within 6 months of the last dose of the 2nd or 3rd platinum-containing chemotherapy regimen.

[0342] ○ Received up to 3 lines of systemic therapy and monotherapy is appropriate as the next line of therapy. Subjects may have received up to one line of therapy after confirmation of platinum resistance.

[0343] ■Neoadjuvant ± adjuvant will be considered as 1 line of therapy.

[0344] ■Maintenance therapy (eg, bevacizumab, PARP inhibitors) will be considered part of the prior line of therapy (will not be counted as a separate line of therapy).

[0345] ■ Hormone therapy will be considered as a separate line of therapy unless used as maintenance.

[0346] ■Changes in therapy due to toxicity in the absence of progression will be considered part of the same line of therapy.

[0347] ○ Subjects must have histologically confirmed advanced, recurrent, or metastatic EC. All histologies (including carcinosarcoma [no more than one subject per dose level]) and molecular subtypes will be included. Subjects may have received prior therapy containing an immune checkpoint inhibitor (ICI) (or are not eligible for ICI therapy) and must not have received more than 2 prior regimens (excluding adjuvant therapy if progression or recurrent / metastatic disease occurred more than 6 months after completing the last cycle of adjuvant therapy).

[0348] ○ Note: There were no restrictions on prior hormone therapy.

[0349] 3. Available tumor tissue (%) for FRA expression by IHC analysis assessed by the vendor. There is no minimum requirement for FRA expression (%). However, the tumor sample must be evaluable for IHC analysis (i.e., of sufficient quality and quantity). Resubmission of samples will be allowed for subjects with a tissue result of "not evaluable" and who meet other criteria. Submitted tumor samples must be archived formalin-fixed, paraffin-embedded (FFPE) tissue blocks, or unstained slides sectioned within 45 days of the most recent FFPE block, or fresh biopsy samples obtained during screening but before starting study treatment.

[0350] 4. Investigator-assessed radiographic disease progression during or after the most recent therapy.

[0351] 5. Measurable disease meeting the following criteria (confirmed by central radiology review only in the dose confirmation section):

[0352] ●At least one lesion with a non-lymph node long-axis diameter >1.0 cm or a lymph node short-axis diameter >1.5 cm that can be serially measured using CT or MRI according to Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1.

[0353] ●According to RECIST 1.1, lesions treated with external-beam radiation therapy (EBRT) or locoregional therapy (eg, radiofrequency (RF) ablation) must show evidence of PD after RT to be considered a target lesion.

[0354] 6. Eastern Cooperative Oncology Group performance status (ECOGPS) of 0 or 1.

[0355] 7. Subjects who are expected to survive at least 3 months after the first administration of study drug.

[0356] 8. Adequate renal function as demonstrated by serum creatinine ≤1.5 mg / dL or calculated creatinine clearance ≥50 mL / minute based on a 12 or 24-hour urine collection.

[0357] 9. Adequate bone marrow function, as follows:

[0358] Absolute neutrophil count (ANC) ≥1.0 x 10 9 / L

[0359] Hemoglobin (Hgb) ≥9.0 g / dL

[0360] Platelet count ≥75 × 10 9 / L

[0361] Growth factors or blood transfusions are permitted according to institutional practice if needed to achieve the above values. Growth factors and platelet transfusions should not be used within 7 days of the start of study treatment.

[0362] 10. Adequate liver function, as follows:

[0363] Total bilirubin ≤1.5 × upper limit of normal (ULN), except for unconjugated hyperbilirubinemia (eg, Gilbert's syndrome)

[0364] Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN (≤ 5 × ULN in the case of liver metastases), unless bone metastases are present. Subjects with alkaline phosphatase (ALP) ≤ 3 × ULN, unless they are known to have bone metastases, in which case higher ALP values ​​are also permitted.

[0365] Albumin >3.0 mg / dL (>3.0 mg / dL).

[0366] 11. Subjects must undergo the required washout period from the end of previous treatment to the first administration of study drug as follows:

[0367] Previous anticancer therapy:

[0368] ● Previous chemotherapy, surgery, radiotherapy: >3 weeks. Previous chest radiotherapy or pneumonectomy are excluded (see exclusion criteria in section 2.2.6).

[0369] ●Antibodies and other biological therapeutics: ≥4 weeks.

[0370] ●Endocrine therapy or small molecule targeted therapy: > 2 weeks.

[0371] ●Immunotherapy: ≥4 weeks.

[0372] 12. Patients with a history of deep vein thrombosis (DVT) within the previous 3 months must have completed at least 1 month of anticoagulation before starting study treatment. Anticoagulation must continue during study treatment.

[0373] 13. Patients at risk for DVT secondary to a central venous catheter or with a history of DVT or clinical symptoms suggestive of DVT must undergo venous Doppler ultrasound to rule out DVT during screening and before starting study treatment.

[0374] 14. If the subject has undergone major surgery, the subject must have fully recovered from the toxicity and / or complications of the intervention before starting study treatment.

[0375] 15. The severity of anticancer therapy-related or radiation-related toxicities has subsided to grade 1 or less, except for stable sensory neuropathy (≤grade 2), anemia (Hgb ≥9.0 g / dL), and alopecia (any grade).

[0376] 16. Subjects must be willing and able to comply with all aspects of the protocol.

[0377] 17. Subjects must provide written informed consent prior to any study-specific screening procedures.

[0378] 2.2.6 Exclusion criteria

[0379] Subjects who met any of the following criteria were excluded from this study:

[0380] 1. Subjects with endometrial leiomyosarcoma, endometrial stromal sarcoma, or high-grade sarcoma.

[0381] 2. Subjects who have previously received any folate receptor targeted agent treatment.

[0382] 3. Subjects with platinum-refractory OC (defined as disease progression during initial platinum-based chemotherapy treatment or within 4 weeks of the last dose).

[0383] 4. Currently enrolled in another clinical study, or using any investigational drug or device that the sponsor believes may interfere with study treatment within the past 28 days or 5 times the half-life of any investigational drug before informed consent (if previous drug therapy falls within the parameters of item 11 of the inclusion criteria, these inclusion criteria should be followed).

[0384] 5. Subjects with brain or subdural metastases are not eligible unless they have completed local therapy and have stopped using corticosteroids for this indication for at least 2 weeks prior to starting treatment in this study. Any signs (e.g., radiographic signs) or symptoms of brain metastases must be stable for at least 4 weeks prior to starting study treatment.

[0385] 6. Diagnosed with meningeal carcinomatosis.

[0386] 7. Any other invasive malignancy that required treatment (except definitive surgery) or showed evidence of recurrence / progression (except complete resection of non-melanoma skin cancer or histologically confirmed carcinoma in situ) within 2 years prior to starting study treatment.

[0387] 8. Significant cardiovascular impairment. History of the following within 6 months before the first dose of study drug: congestive heart failure greater than New York Heart Association (NYHA) class II; unstable angina; myocardial infarction; stroke; arrhythmia associated with hemodynamic instability.

[0388] 9. Clinically significant ECG abnormalities, including significantly prolonged baseline QT using Fridericia's formula (QTcF) correction (repeated demonstration of QTcF interval >500ms), history of risk factors for Torsades de Pointes (e.g., heart failure, hypokalemia, family history of long QT syndrome), or use of concomitant medications that prolong QTcF.

[0389] 10. Known to be Human Immunodeficiency Virus (HIV) positive. Testing upon entry is not required.

[0390] 11. Active viral hepatitis (B or C, as demonstrated by positive serology). If no symptoms or history are present, no testing is required upon entry, except as required by local requirements.

[0391] 12. Females who are lactating or pregnant at screening or baseline (documented by a positive beta human chorionic gonadotropin (B-hCG) or human chorionic gonadotropin (hCG) with a minimum sensitivity of 25 IU / L or equivalent units of beta-hCG (or hCG)). A separate baseline assessment is required if a negative screening pregnancy test is obtained more than 72 hours prior to the first administration of study drug.

[0392] 13. Women of childbearing potential who:

[0393] ○ Not using highly effective contraceptive methods within 28 days prior to study entry, including any of the following:

[0394] ■Complete abstinence (if this is their preferred and normal lifestyle)*

[0395] Intrauterine contraceptive device or intrauterine hormone-releasing system (IUS)

[0396] ■Contraceptive implants

[0397] ■Oral contraceptives (subjects must take a stable dose of the same oral contraceptive for at least 28 days before dosing and throughout the study and for 90 days after study drug discontinuation)

[0398] ■Having a vasectomized partner with confirmed azoospermia

[0399] ○ Do not agree to use highly effective contraceptive methods (as described above) throughout the study and for 90 days after study drug discontinuation.

[0400] For sites outside the EU, it is permitted that if highly effective contraceptive methods are not suitable or accepted by the subject, the subject must agree to use a medically acceptable method of contraception, i.e., a double barrier method of contraception, such as a latex or synthetic condom plus a diaphragm or a cervical / vault cap with spermicide. NOTE: All females will be considered of childbearing potential unless they are postmenopausal (amenorrhea for at least 12 consecutive months, in the appropriate age group, and with no other known or suspected cause) or have been surgically sterilized (i.e., bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all performed at least 1 month prior to dosing).

[0401] *Sexual abstinence is considered a highly effective approach only when defined as abstention from heterosexual intercourse during the entire risk period associated with the study intervention. The reliability of sexual abstinence needs to be assessed based on the duration of the study and the subjects’ preferred and usual lifestyle.

[0402] 14. For dose escalation only: Men who have had an unsuccessful vasectomy (confirmed azoospermia) or they and their female partners do not meet the above criteria (i.e., are not of childbearing potential or using highly effective contraception throughout the study period and for 90 days after study drug discontinuation). Men who do not agree to use latex or synthetic condoms throughout the study period and for 90 days after study drug discontinuation if their female partner becomes pregnant. Sperm donation is not permitted during the study period and for 90 days after study drug discontinuation.

[0403] 15. Abnormal pulmonary function test (PFT): FEV1 / FVC < 0.7, FEV1 or FVC < 80%, DLCO < 80%.

[0404] 16. Current ILD / pneumonitis, or suspected ILD / pneumonitis at screening, or history of interstitial lung disease (ILD) / pneumonitis of any severity, including ILD / pneumonitis caused by previous anticancer therapy.

[0405] 17. Current infectious pneumonia, history of viral pneumonia.

[0406] 18. Clinically significant lung-specific disease, including but not limited to any underlying pulmonary disorder (e.g., pulmonary embolism), asthma, chronic obstructive pulmonary disease (COPD), and restrictive lung disease.

[0407] 19. Clinically significant pleural effusion or pericardial effusion.

[0408] 20. Previous pneumonectomy.

[0409] 21. History of chest radiotherapy. Subjects with a history of chest radiotherapy may be allowed if chest radiotherapy is documented >2 years before starting study treatment.

[0410] 22. Any autoimmune, connective tissue, or inflammatory disorder with lung involvement.

[0411] 23. Known history of active tuberculosis (Mycobacterium tuberculosis).

[0412] 24. Surgery is planned during the study, except for minor surgery that will not delay study treatment.

[0413] 25. Active infection of clinical significance (in the opinion of the investigator) requiring systemic treatment within 2 weeks prior to the first dose of study drug.

[0414] 26. Have received a live attenuated vaccine within 4 weeks before the first dose of the study drug, or anticipate the need for such a live attenuated vaccine during the study. Inactivated vaccines (e.g., hepatitis A or polio vaccines) are permitted during the study. Seasonal influenza and COVID-19 vaccines that do not contain live viruses are permitted.

[0415] 27. Any previous hypersensitivity reaction to the monoclonal antibodies or contraindications to receiving corticosteroids or any of the excipients (investigators should refer to the prescribing information of the selected corticosteroid).

[0416] 28. Known intolerance to any component of the study medication.

[0417] 29. Any medical or other condition that the investigator believes would prevent the subject from participating in the clinical study.

[0418] 30. Receipt of any medication that is prohibited from being used in combination with one or more study treatment drugs, as stated in the eribulin product label, unless the medication is discontinued within 7 days prior to enrollment.

[0419] 31. Known mental or substance abuse disorder that would interfere with compliance with trial requirements.

[0420] 2.2.7 Study treatment

[0421] Administration regimen: MORAb-202 will be administered as an IV infusion every 3 weeks. One administration cycle is defined as 21 days (also referred to as Q3W). The concentration of the study drug in the vial is 10 mg / mL. The first infusion of MORAb-202 will be administered over no less than 60 minutes. If no infusion reaction is observed, subsequent infusions may be administered as tolerated, but the infusion time will be no less than 30 minutes.

[0422] 2.2.8 Concomitant medications / therapies

[0423] Prophylaxis for nosocomial infections, acceptable treatment for DLT events, or ongoing treatment for AE complications is permitted, provided that concomitant therapy is kept to a minimum during this study. G-CSF or equivalent may be used at the discretion of the investigator in accordance with institutional or national guidelines.

[0424] In consultation with the sponsor, radiation therapy for symptomatic, solitary, nontarget lesions may be permitted during study treatment (up to two times). Any brain lesion requiring radiation therapy is indicative of progressive disease.

[0425] Acceptable treatment for adverse events (e.g., ILD) or ongoing treatment for complications of adverse events (e.g., ILD) was allowed. Acceptable treatment included administration of corticosteroids, such as dexamethasone. Dexamethasone 4 mg was taken orally twice daily from day 1 to day 3 of each cycle of MORAb-202.

[0426] 2.2.9 Evaluation

[0427] Efficacy, safety, PK, and PD will be evaluated.

[0428] 2.2.10 Bioanalytical methods

[0429] Serum MORAb-202 concentrations will be measured using a drug-antibody ratio (DAR)-tolerant ligand-binding assay format designed to specifically quantify toxin-conjugated antibodies (DAR ≥ 1), where any intact molecule with at least one DAR is detected. Serum total antibody concentrations will be measured using a validated ligand-binding assay format designed to detect farletuzumab regardless of the level of linker-toxin conjugation present (DAR ≥ 0). Total eribulin concentrations will be measured using a validated liquid chromatography tandem mass spectrometry (LC-MS / MS) method. Anti-drug antibodies (ADA) will be measured using a validated ligand-binding assay.

[0430] 2.2.11 Independent Data Monitoring Committee (IDMC)

[0431] Safety monitoring will be performed by the IDMC. The functions and membership of the IDMC will be described in the IDMC Charter.

[0432] The first IDMC will be conducted after the first 6 subjects have been treated (first cohort) and observed for 6 weeks (the time point for the first scheduled assessment of tumor assessments and ILD assessments in the first study), and then after each cohort. If a subject discontinues study treatment for any reason other than drug-related toxicity before completing the first 6 weeks of study treatment, the subject will be replaced. If ≥2 cases of ≥Grade 3 ILD / pneumonitis events are observed in the study, the sponsor will suspend enrollment pending IDMC review. The timing of IDMC reviews may also be adjusted or held more frequently if the sponsor's ongoing safety monitoring deems it necessary.

[0433] 2.2.12 Basic principles of sample size

[0434] The primary objective of the dose escalation portion is to evaluate safety and tolerability and determine the RP2D of MORAb-202 in subjects with selected tumor types (OC, EC, NSCLC, TNBC). The sample size for this portion is approximately 36 subjects, depending on the number of DLTs observed. Additional OC subjects will be accumulated as backfill to achieve approximately 10 OC subjects per dose level.

[0435] The primary objective of the dose confirmation portion of this study is to evaluate the safety and preliminary efficacy of MORAb-202 in OC and EC subjects. The planned number of subjects is approximately 30. This portion consists of cohorts of 6 or 9 subjects, with approximately 15 subjects at each dose level of 25 mg / m2 and 33 mg / m2 of MORAb-202. The order in which the cohorts are performed depends on the number of Grade ≥3 ILD events observed. The earlier cohorts will enroll OC and EC subjects, and the last cohort or cohorts will enroll only EC subjects (see study protocol).

[0436] The data from these cohorts will be analyzed to determine one or more regimens that are acceptable for further study. Acceptable regimens will be determined based on the degree of management of ILD in these cohorts treated according to the methods described herein.

[0437] Example 3

[0438] 3.1 Study design

[0439] A Phase 2, open-label, randomized, multicenter study was conducted to evaluate the safety, efficacy, and tolerability of MORAb-202 in participants with metastatic NSCLC AC (adenocarcinoma). Participants will be randomized 1:1 to receive 33 mg / m2 of MORAb-202 every 3 weeks in Group A. 2 MORAb-202, in group B, received 25 mg / m 2 .

[0440] The following participants will be included in the study:

[0441] Participants with no genomic alterations or with unknown genomic alterations in the metastatic setting after receiving:

[0442] ●Prior treatment with platinum-doublet chemotherapy and anti-PD-1 / PD-L1 therapy, given concurrently or sequentially

[0443] ●No more than 2 lines of systemic therapy (no more than 1 prior line of chemotherapy)

[0444] Participants with known genomic alterations in the metastatic setting after receiving:

[0445] ●At least one approved targeted therapy

[0446] ●No more than 3 lines of systemic therapy (no more than 1 line of chemotherapy)

[0447] Approximately 60 participants will be randomized in a 1:1 ratio stratified by ECOGPS 0 vs. 1 to 1 of the following treatment groups:

[0448] Group A (N=30): MORAb-202 33 mg / m 2 Q3W

[0449] Group B (N=30): MORAb-202 25 mg / m 2 Q3W

[0450] All participants will be treated until investigator-assessed disease progression according to RECIST v1.1, unacceptable toxicity, withdrawal of consent for study treatment, death, or end of study, whichever occurs first. The maximum duration of treatment will be up to 2 years; however, ongoing safety and tumor assessments will guide the decision whether to continue participants for additional cycles of study therapy beyond 2 years if the participant has confirmed clinical benefit.

[0451] To further characterize the safety and efficacy of the selected dose, up to 30 additional participants may be enrolled in either arm A or arm B to ensure that at least 30 FRA-evaluable participants are enrolled in each cohort and approximately 25% of FRA high expressers are enrolled. All relevant data (safety, efficacy, PK, and PD) will inform the sponsor's decision on subsequent clinical development, including enrolling more participants in expansion cohorts to evaluate the relationship with FRA expression through protocol amendments or continuing development in a separate study.

[0452] The primary analysis will be performed when all participants in each group have been treated and have received at least 6 months of follow-up or have stopped treatment early. One dose level of MORAb-202 will be selected in the primary analysis to continue further evaluation. Dose selection will be based on the overall efficacy and safety data. Safety follow-up visits will be conducted 30 days after the last study drug administration. All ongoing treatment-related SAEs and ILD / pneumonitis events will be followed until resolved or stable. All participants who discontinue treatment for reasons other than disease progression will be followed up for ongoing tumor imaging assessments until the occurrence of disease progression assessed by the investigator according to RECIST v1.1, death, or withdrawal of consent for tumor assessment, whichever occurs first. All participants will receive survival follow-up every 3 months until all randomized participants complete 2 years of survival follow-up.

[0453] The study design is shown in the figure below. Figure 6 shown.

[0454] 3.1.1 Objectives

[0455] 3.1.1.1 Primary objectives and endpoints

[0456] The primary objectives of this study are to: (i) evaluate the safety and tolerability of MORAb-202 in participants with previously treated non-small cell lung cancer (NSCLC) adenocarcinoma (AC) and (ii) evaluate tumor responses to MORAb-202 in participants with previously treated NSCLC AC.

[0457] The primary endpoints of this study were: (i) the incidence and severity of adverse events (AEs) / serious AEs (SAEs), treatment-related AEs / SAEs, AEs leading to discontinuation, AEs of special interest (AESIs), deaths, and laboratory abnormalities, and (ii) objective response rate (ORR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 based on investigator assessment.

[0458] 3.1.1.2 Secondary objectives and endpoints

[0459] The secondary objectives of this study are to: (i) evaluate progression-free survival (PFS) of MORAb-202 in participants with previously treated NSCLC AC; (ii) evaluate DCR of MORAb-202 in participants with previously treated NSCLC AC; and (iii) evaluate duration of response (DoR) of MORAb-202 in participants with previously treated NSCLC AC who achieve a CR or PR.

[0460] Secondary endpoints of this study were: (i) PFS according to RECIST v1.1, as assessed by the investigator; (ii) DCR according to RECIST v1.1, as assessed by the investigator; and (iii) DoR according to RECIST v1.1, as assessed by the investigator.

[0461] 3.2 Number of subjects

[0462] Approximately 60 participants will be randomized in a 1:1 ratio to one of 2 treatment groups, with approximately 30 participants in each group. Assuming a screen failure rate of approximately 40%, it is estimated that approximately 100 participants will be enrolled to achieve approximately 60 randomized participants. Randomized participants who discontinue before receiving the first dose of MORAb-202 will be replaced.

[0463] 3.3 Inclusion criteria

[0464] Participants were eligible for inclusion in the study only if they met all of the following criteria:

[0465] 1) Sign the written informed consent

[0466] a) The participant or a legally acceptable representative (LAR; if acceptable within local guidelines) must sign and date the written ICF approved by the Institutional Review Board (IRB) / Independent Ethics Committee (IEC) in accordance with regulatory, local and institutional guidelines. This must be obtained prior to performing any protocol-related procedures that are not part of normal patient care.

[0467] b) Participants must be willing and able to comply with scheduled visits, treatment schedules, laboratory tests, and other requirements of the study.

[0468] 2) Participant Type and Target Disease Characteristics

[0469] a) Histologically or cytologically documented metastatic NSCLC AC (defined by the 8th International Association for the Study of Lung Cancer Classification).

[0470] b) Participants with no genomic alterations or unknown genomic alterations in the metastatic setting after receiving:

[0471] i) Prior treatment with platinum-doublet chemotherapy and anti-PD-1 / PD-L1 therapy, given simultaneously or sequentially

[0472] ii) No more than 2 lines of systemic therapy (no more than 1 prior line of chemotherapy)

[0473] c) Participants with known genomic alterations in the metastatic setting:

[0474] i) At least 1 approved targeted therapy

[0475] ii) No more than 3 lines of systemic therapy (no more than 1 line of chemotherapy)

[0476] d) Radiographically documented disease progression during or after the last treatment as assessed by the investigator

[0477] e) Measurable target disease assessed by the investigator according to RECIST v1.1.

[0478] f) According to RECIST v1.1, lesions that have been treated with external-beam radiation therapy (EBRT) or locoregional therapy (eg, radiofrequency (RF) ablation) must show signs of disease progression to be considered target lesions.

[0479] g) ECOGPS with 0 or 1

[0480] h) Toxicity from prior anticancer therapy resolved to Grade 1 (NCI CTCAE v5.0) or less severity prior to administration of study drug, with the exception of stable sensory neuropathy (≤Grade 2), anemia (hemoglobin [Hgb] ≥9.0 g / dL), and long-term sequelae (e.g., alopecia, fatigue) that are not expected to interfere with study treatment.

[0481] i) FFPE tissue or newly obtained biopsies must be available for evaluation by IHC at a central laboratory prior to randomization. Tumor samples (tissue blocks [preferred] or 15 unstained slides) must be evaluable for IHC analysis (i.e., sufficient quality and quantity) to meet the eligibility criteria for randomization. For subjects with insufficient tissue quality and quantity who meet other criteria, resubmission of samples will be allowed.

[0482] 3) Age of participants

[0483] ● Participants (male or female) must be 18 years of age or older when signing the informed consent form.

[0484] 4) Fertility status

[0485] ●Investigators should counsel women of childbearing potential (WOCBP) and male participants who have sex with WOCBP about the importance of preventing pregnancy, the implications of unintended pregnancy, and the potential for fetal toxicity due to transmission of the study intervention (present in semen) to the developing fetus, even if the participant has undergone a successful vasectomy or their partner is pregnant.

[0486] ●Investigators should assess the effectiveness of contraceptive methods associated with the first dose of the study intervention.

[0487] ●Local laws and regulations may require the use of alternative and / or additional contraceptive methods.

[0488] a) Female participants:

[0489] i) Female participants must provide documentary proof in their medical files that they are not of childbearing potential.

[0490] ii) Women who are infertile are exempt from the contraceptive requirement.

[0491] iii) WOCBP must have a negative high-sensitivity serum or urine pregnancy test (minimum sensitivity 25 IU / L or equivalent HCG units) within 24 hours before the start of the study intervention.

[0492] (1) If the urine test cannot be confirmed to be negative (e.g., the result is inconclusive), a serum pregnancy test is required. In this case, if the serum pregnancy result is positive, the participant must be excluded.

[0493] (2) Investigators were responsible for reviewing medical history, menstrual history, and recent sexual activity to reduce the risk of inclusion of women with undetected early pregnancy.

[0494] iv) The WOCBP must agree to follow instructions for one or more contraceptive methods as described below and included in the ICF.

[0495] o WOCBP are allowed to use hormonal contraceptive methods.

[0496] v) Female participants are eligible to participate if they are not pregnant or breastfeeding and meet at least one of the following criteria:

[0497] (1) Not a WOCBP

[0498] or

[0499] (2) Be WOCBP and use highly effective (failure rate <1% per year), low user-dependency contraceptive methods during the intervention period and at least 28 days before dosing, throughout the study, and within 90 days after MORAb-202 discontinuation, and agree not to donate eggs (eggs, oocytes) for reproductive purposes during the same time period.

[0500] b) Male participants:

[0501] Men who are sexually active with a WOCBP must agree to follow instructions for one or more of the contraceptive methods described below.

[0502] i) Azoospermic men are not exempt from contraception requirements and will be required to use latex or other synthetic condoms at all times during any sexual activity (e.g., vaginal, anal, oral) with a WOCBP, even if the participant has had a successful vasectomy or their partner is pregnant.

[0503] ii) Male participants will be required to use latex or other synthetic condoms at all times during any sexual activity (e.g., vaginal, anal, oral) with a WOCBP, even if the participant has had a successful vasectomy or their partner is pregnant or lactating. Men should continue to use condoms during the intervention period, for at least 28 days prior to dosing, throughout the study, and for 90 days after discontinuation of MORAb-202.

[0504] iii) Female partners of male participants in the study should be advised to use highly effective contraceptive methods during the intervention period and for at least 90 days after the last dose of the study intervention for the male participant.

[0505] iv) Male participants with pregnant or breastfeeding partners must agree to remain abstinent or use male condoms during any sexual activity (e.g., vaginal, anal, oral) during the intervention period and for at least 90 days after the last dose of the study intervention, even if the participant has had a successful vasectomy.

[0506] v) Male participants must refrain from donating sperm during the intervention period and for at least 90 days after the last dose of the study intervention.

[0507] vi) Breastfeeding partners should be advised to consult their health care provider regarding the use of appropriate highly effective contraceptive methods during the period in which participants are required to use condoms.

[0508] 3.4 Exclusion criteria

[0509] Participants were excluded from the study if they met any of the following criteria:

[0510] 1) Medical conditions

[0511] a) NSCLC histology other than AC (ie, squamous cell carcinoma; large cell carcinoma).

[0512] b) Abnormal pulmonary function test (PFT): forced expiratory volume 1 (FEV1) < 70%, or forced vital capacity (FVC) < 60%, or diffusion capacity of the lung for carbon monoxide (DLCO) < 80%.

[0513] c) Clinically significant lung-specific disease that cannot be managed medically, including but not limited to any underlying pulmonary disorder (e.g., pulmonary embolism), asthma, chronic obstructive pulmonary disease (COPD), and restrictive lung disease.

[0514] d) Clinically significant pleural or pericardial effusion requiring drainage or ascites requiring peritoneal shunt or CART (concentrated ascites re-infusion therapy)

[0515] e) Previous pneumonectomy. Previous lobectomy and segmentectomy performed >12 months before treatment were allowed.

[0516] f) Recent Chest Radiotherapy. Participants who received chest or chest wall radiotherapy were allowed if chest radiotherapy was documented >12 months before starting study treatment.

[0517] g) Current infectious pneumonia, history of viral pneumonia (including COVID-19 related infection) with evidence of persistent radiological abnormalities.

[0518] i) Prior SARS-CoV-2 infection, suspected or confirmed within 4 weeks before randomization. In addition, acute symptoms must have resolved completely and there must be no sequelae that would put the participant at higher risk for study treatment, as assessed by the investigator in consultation with the BMS Medical Monitor (or designee).

[0519] ii) Participants currently enrolled in an ongoing COVID-19 intervention trial must not participate in a BMS clinical study until a specific washout period has been reached. If a study participant has received an investigational COVID-19 vaccine or other IP intended to treat or prevent COVID-19 prior to screening, enrollment must be delayed until the biological effects of the vaccine or IP have stabilized, as determined by a written discussion between the investigator and the Medical Monitor (or designee).

[0520] NOTE: Based on specific country / regional guidelines, a COVID-19 polymerase chain reaction (PCR) viral test may be required prior to randomization and the results of this test may impact study participation. Test results should be discussed with the BMS Medical Monitor (or designee) to confirm eligibility.

[0521] h) Current ILD / pneumonitis assessed by the investigator, or suspected ILD / pneumonitis at screening or history of ILD / pneumonitis of any severity, including ILD / pneumonitis caused by previous anticancer therapy.

[0522] i) Spinal cord compression or untreated symptomatic central nervous system (CNS) metastases (brain or leptomeningeal). Participants were eligible if the CNS metastases were asymptomatic and did not require immediate treatment, or if these metastases had been treated and there was no evidence of progression on MRI or CT for at least 4 weeks after completion of treatment and within 28 days prior to the first dose of study treatment and the participant had recovered neurologically to baseline (except for residual signs or symptoms related to CNS treatment). In addition, participants must have discontinued anticonvulsant therapy and must have been off corticosteroids or on a stable or decreasing dose of ≤10 mg prednisone (or equivalent) daily for at least 2 weeks prior to treatment. Imaging performed within 28 days prior to treatment must document the radiographic stability of CNS lesions and be performed after completion of any CNS-directed therapy.

[0523] j) Participants with conditions requiring systemic treatment with corticosteroids >10 mg daily prednisone equivalents or other immunosuppressive medications, excluding steroid adrenal replacement medications >10 mg daily prednisone equivalents, within 14 days of study treatment administration were allowed in the absence of active autoimmune disease.

[0524] i) Treatment with a short-term (<5 days) course of steroids for up to 7 days prior to starting study treatment was permitted.

[0525] k) Evidence of active infection ≤ 14 days prior to treatment, including tuberculosis and uncontrolled infection requiring systemic antibacterial, antiviral, or antifungal therapy.

[0526] i) Uncontrolled or severe cardiovascular disease within 6 months prior to enrollment, including but not limited to any of the following: cardiac angioplasty or stenting, myocardial infarction, unstable angina, coronary artery bypass graft surgery, symptomatic peripheral vascular disease, grade III or IV congestive heart failure (according to the definition of the New York Heart Association), pericarditis or myocarditis.

[0527] ii) Sustained symptomatic arrhythmia with a history of clinically significant arrhythmia (e.g. ventricular tachycardia, ventricular fibrillation or torsade de pointes).

[0528] l) Clinically significant ECG abnormalities, including significantly prolonged baseline QTcF (repeated demonstration of QTcF interval >500 msec), history of risk factors for Torsades de Pointes (e.g., heart failure, hypokalemia, family history of long QT syndrome), or use of concomitant medications that prolong QTcF.

[0529] m) Evidence of active bleeding or medically significant bleeding within 3 months prior to enrollment.

[0530] n) History of deep vein thrombosis (DVT) within 6 weeks prior to enrollment. Participants who completed at least 1 month of anticoagulation before starting study treatment and continued during the study were eligible.

[0531] i) Participants at risk for DVT secondary to a central venous catheter or with a previous history of DVT or clinical symptoms suggestive of DVT must undergo venous Doppler ultrasound to rule out DVT during screening and before starting study treatment.

[0532] o) Any autoimmune, connective tissue, or inflammatory disorder with documented (or suspected) lung involvement (e.g., rheumatoid arthritis, Sjögren's syndrome, sarcoidosis, etc.).

[0533] p) Concurrent malignancy requiring treatment (present during screening), or history of prior malignancy active within 2 years prior to randomization, excluding NSCLC on study (i.e., participants with a history of prior malignancy were eligible if treatment was completed at least 2 years prior to randomization and the participant had no evidence of disease). Participants with a history of prior early-stage basal / squamous cell skin cancer or non-invasive or in situ carcinoma (i.e., superficial bladder cancer, prostate carcinoma in situ, cervical cancer, or breast cancer) who had received definitive treatment at any time were also eligible.

[0534] q) Any condition, including medical, emotional, psychiatric, or logistical conditions, that the investigator believes would prevent the participant from complying with the protocol or would increase the risks associated with study participation or study drug administration or interfere with the interpretation of safety results.

[0535] 2) Previous / concomitant therapy

[0536] a) Participants who have received prior investigational treatment with a FRA-targeted agent or FRA-targeted ADC, including MORAb-202.

[0537] b) Any condition requiring folic acid supplementation (e.g., folic acid deficiency).

[0538] c) Participants with known intolerance to study drug components.

[0539] d) Currently enrolled in another clinical study or using any study drug or device that the sponsor believes may interfere with the study treatment within the past 28 days or within 5 times the half-life of the study drug before the start of study treatment (whichever is longer).

[0540] e) Any major surgery within 4 weeks of the first dose of study treatment. Participants must have recovered from the effects of major surgery or major trauma for at least 14 days prior to the first dose of study treatment.

[0541] f) Received any live / attenuated vaccine within 30 days of the first study treatment.

[0542] 3) Physical and laboratory test results

[0543] a) Evidence of organ dysfunction or any clinically significant deviation from normal values ​​on physical examination, vital signs, ECG, or clinical laboratory measurements outside of the range consistent with the target population

[0544] i) Renal insufficiency demonstrated by serum creatinine >1.5 mg / dL or calculated creatinine clearance (CrCL) <50 mL / min based on a 12 or 24-hour urine collection.

[0545] ii) Insufficient bone marrow function as follows:

[0546] (1) Absolute neutrophil count (ANC) <1.0×108T 9 8T / L

[0547] (2) Hgb < 9.0 g / dL

[0548] (3) Platelet count <75 × 10 9 / L

[0549] NOTE: Supportive therapies required to achieve the above values, such as blood / platelet transfusions, hematopoietic stimulants including granulocyte colony stimulating factor (G-CSF) preparations, were allowed per institutional practice if given ≥1 week prior to study treatment.

[0550] iii) Insufficient liver function as shown below:

[0551] (1) Total bilirubin >1.5× upper limit of normal (ULN), except for unconjugated hyperbilirubinemia (e.g., Gilbert's syndrome, in which total bilirubin must be <3×ULN).

[0552] (2) ALT and aspartate aminotransferase (AST) > 3×ULN (> 5×ULN in the case of liver metastases), unless there are bone metastases. Participants with alkaline phosphatase (ALP) > 3×ULN, unless they are known to have bone metastases, in which case higher ALP values ​​are also allowed.

[0553] iv) Serum albumin <3.0 g / dL.

[0554] b) Known human immunodeficiency virus (HIV) positive and had AIDS defined as an opportunistic infection within the past year or a current CD4 count <350 cells / μL. HIV-infected participants were eligible if:

[0555] i) They were receiving antiretroviral therapy (ART) for at least 4 weeks prior to randomization as clinically indicated at the time of study entry

[0556] ii) They continued to take ART as clinically indicated at the time of study entry

[0557] iii) CD4 count and viral load monitored by local healthcare providers as per standard of care

[0558] Note: HIV testing must be performed at a locally mandated location. HIV-positive participants must be excluded where locally mandated.

[0559] c) Active viral hepatitis B or C, as indicated by:

[0560] i) Any positive test result for Hepatitis B virus (HBV), indicating the presence of the virus, such as Hepatitis B surface antigen (HBsAg, Australia antigen) positivity.

[0561] ii) Any positive test result for hepatitis C virus (HCV), indicating the presence of active viral replication (detectable HCV-ribonucleic acid [RNA]). Note: Participants with positive HCV antibodies and undetectable HCV RNA are eligible for enrollment.

[0562] iii) Additional or alternative testing to rule out infection is permitted per institutional guidelines.

[0563] 4) Allergies and adverse drug reactions

[0564] a) Any previous severe hypersensitivity reaction (≥Grade 3) to the monoclonal antibody or eribulin, or contraindications to receiving corticosteroids or any of the excipients.

[0565] 5) Other exclusion criteria

[0566] a) Involuntarily incarcerated prisoners or participants. (Note: In certain specific circumstances, in countries where local regulations allow, incarcerated persons may be included or allowed to continue as participants only. Strict conditions apply and approval by BMS is required.)

[0567] b) Participants who are involuntarily detained for treatment of mental or physical illness (e.g. infectious disease).

[0568] 3.5 Study intervention

[0569] MORAb-202 will be administered to subjects according to Table 16 below:

[0570] Table 16. Study Interventions in CA116003

[0571]

[0572] AxMP, ancillary medicinal product; IMP, investigational medicinal product; IV, intravenous; NIMP, noninvestigational medicinal product; Q3W, every 3 weeks.

[0573] 3.6 Dosage Adjustment

[0574] For participants who experience toxicity but meet the criteria for dose modification, the next MORAb-202 administration should be reduced by 1 dose level. Details are shown in Table 17. The study medical monitor needs to be consulted before the dose is reduced. Once the dose is reduced, it cannot be increased.

[0575] Table 17. Dose Adjustments for Subjects Experiencing Toxicity

[0576]

[0577] Example 4

[0578] 4.1 Research details

[0579] A Phase 2, open-label, randomized, multicenter study will evaluate the safety, efficacy, and tolerability of MORAb-202 in female participants with platinum-resistant high-grade serous (HGS) ovarian, primary peritoneal, or fallopian tube cancer. The study hypothesis is that MORAb-202 at 33 mg / m 2 or 25 mg / m 2 The study showed a favorable benefit-risk profile, as measured by overall response rate (ORR) and safety profile in participants with platinum-resistant high-grade serous ovarian, primary peritoneal, or fallopian tube cancer. The study duration was approximately 4 years.

[0580] 4.1.1 Objectives

[0581] 4.1.1.1 Main objectives

[0582] The primary objectives of the study were to: (i) compare objective response rate (ORR) with MORAb-202 versus investigator's choice (IC) chemotherapy (among all randomized participants); and (ii) assess the proportion of participants in each group experiencing treatment-related adverse events (TRAEs) leading to study drug discontinuation within 6 months after the first dose of study drug, among all treated participants.

[0583] The endpoints of the above primary objective were: (i) objective response rate (ORR) according to investigator assessment by RECIST v1.1; and (ii) TRAEs leading to discontinuation.

[0584] 4.1.1.2 Secondary Objectives

[0585] The secondary objectives of the study are: (i) to evaluate the disease control rate (DCR) of MORAb-202 and IC chemotherapy in all randomized participants; (ii) to evaluate the duration of response (DoR) of MORAb-202 and IC chemotherapy in all randomized participants; and (iii) to evaluate the progression-free survival (PFS) of MORAb-202 and IC chemotherapy in all randomized participants. The endpoints of the above secondary objectives are: (i) DCR according to investigator assessment by RECIST v1.1; (ii) DoR according to investigator assessment by RECIST v1.1; and (iii) PFS according to investigator assessment by RECIST v1.1.

[0586] 4.2 Study design

[0587] Participants will be randomly assigned in a 2:2:1 ratio to the following treatment groups:

[0588] Group A (N = 60): 33 mg / m every 3 weeks (21-day cycle) 2 Administer MORAb-202 (optionally reduce dose to 25 mg / m 2 ).

[0589] Group B (N = 60): 25 mg / m every 3 weeks (21-day cycle) 2 Administer MORAb-202 (optionally reduce dose to 17 mg / m 2 ).

[0590] ● Group C (N=30): Administered IC single-agent chemotherapy selected from the following:

[0591] ○ 80 mg / m on days 1, 8, 15, and 22 of a 28-day cycle 2 IV paclitaxel; or

[0592] ○ 40 mg / m on day 1 of a 28-day cycle 2 IV pegylated liposomal doxorubicin (PLD); or

[0593] ○ 4 mg / m on days 1, 8, and 15 of a 28-day cycle 2 IV topotecan or 1.25 mg / m for 5 consecutive days on days 1 to 5 of a 21-day cycle 2 .

[0594] MORAb-202 will be administered as an IV infusion.

[0595] Participants will be randomized based on FRA expression (≥75% tumor staining vs. <75% tumor staining) and number of prior lines of therapy (1 vs. 2-3).

[0596] All participants will be treated until investigator-assessed disease progression per RECIST v1.1, unacceptable toxicity, participant withdrawal of consent to receive study treatment, death, or end of study, whichever occurs first. The maximum duration of treatment will be up to 2 years; however, ongoing safety and tumor assessments will guide the decision whether to continue participants for additional cycles of study therapy beyond 2 years if the participant has confirmed clinical benefit.

[0597] An overview of the study design is as follows Figure 7 shown.

[0598] 4.3 Number of participants

[0599] Approximately 150 participants will be randomized in a 2:2:1 ratio to 1 of 3 treatment groups, with approximately 60 participants in each MORAb-202 group (Groups A and B) and 30 participants in the chemotherapy group (Group C). Assuming a screen failure rate of approximately 25%, it is estimated that approximately 200 participants will be enrolled to achieve approximately 150 randomized participants.

[0600] 4.4 Inclusion criteria

[0601] The main inclusion criteria for participants in the study were as follows. Participants had to meet all of the following to be eligible for inclusion in the study:

[0602] ●Female participants with histologically confirmed HGS ovarian, primary peritoneal, or fallopian tube cancer.

[0603] Platinum-resistant disease, defined as:

[0604] ●For participants who have received only 1 prior line of platinum-based therapy: progression >1 month to ≤6 months after the last dose of at least 4 cycles of platinum-based therapy.

[0605] ●For participants who have received 2 or 3 lines of platinum-based therapy: Progression ≤ 6 months after the last dose of platinum-based therapy.

[0606] ● Participants have received at least 1 but no more than 3 prior lines of systemic therapy and monotherapy is appropriate as the next line of therapy. Participants may have received up to 1 line of therapy after confirmation of platinum resistance.

[0607] ● Participants must have previously received bevacizumab or must have been deemed medically unsuitable or ineligible / intolerant to receive bevacizumab, refused bevacizumab, or were unable to receive bevacizumab due to unavailability of bevacizumab.

[0608] ● Note: (i) Neoadjuvant ± adjuvant chemotherapy will be considered as 1 line of therapy. (ii) Maintenance therapy (e.g., bevacizumab, PARP inhibitors) will be considered as part of the prior line of therapy. (iii) Changes in therapy in the absence of progression will be considered as part of the same line of therapy.

[0609] ●Disease progression according to RECIST v1.1 (by investigator assessment) with at least one measurable lesion on or after most recent therapy. Formalin-fixed, paraffin-embedded (FFPE) tissue (up to 5 years) or newly obtained biopsy must be available for FRA assessment prior to randomization. Tumor samples (preferably tissue blocks or at least 15 unstained slides) must be evaluable for FRA IHC analysis to meet eligibility criteria. Resubmission of samples will be allowed for participants with non-evaluable FRA IHC who meet other criteria.

[0610] Eastern Cooperative Oncology Group performance status (ECOGPS) of 0 or 1.

[0611] ●Participants must be ≥18 years of age (or the legal age of consent in the jurisdiction where the study is located) when signing the informed consent form (ICF).

[0612] 4.5 Exclusion criteria

[0613] Participants were excluded from the study if any of the following were true:

[0614] ●Clear cell, mucinous, endometrioid, or sarcomatous histology, or mixed tumors containing any of these histologic components, or low-grade or borderline ovarian cancer.

[0615] ●Primary platinum-refractory ovarian cancer, defined as disease progression within one month after the last dose of a first-line platinum-containing regimen.

[0616] ●Abnormal pulmonary function tests (PFTs): FEV1 <70% or FVC <60%, and DLCO <80%.

[0617] ●Current ILD / pneumonitis assessed by the investigator, or suspected ILD / pneumonitis at screening or history of ILD / pneumonitis of any severity, including ILD / pneumonitis caused by previous anticancer therapy.

[0618] ●Current infectious pneumonia, history of viral pneumonia (including COVID-19-related infection), and evidence of persistent radiographic abnormalities.

[0619] ● Significant third space fluid retention (eg, ascites or pleural effusion) requiring repeated drainage.

[0620] ●Clinically significant pericardial effusion requiring drainage.

[0621] ● Previous pneumonectomy. Previous lobectomy and segmentectomy performed >12 months before treatment were allowed.

[0622] ●Recent thoracic radiotherapy. Participants who received thoracic or chest wall radiotherapy were allowed if the radiotherapy was documented >6 months before starting study treatment (eg, history of breast cancer).

[0623] ● Any autoimmune, connective tissue, or inflammatory disorder with documented (or suspected) pulmonary involvement (eg, rheumatoid arthritis, Sjögren's syndrome, sarcoidosis, etc).

[0624] ● Spinal cord compression or untreated symptomatic central nervous system (CNS) metastases. Participants were eligible if the CNS metastases were asymptomatic and did not require immediate treatment, or had been treated and the participant's neurologic function had returned to baseline (except for residual signs or symptoms related to CNS treatment). In addition, participants had discontinued anticonvulsant therapy and must have been off corticosteroids or on a stable or decreasing dose of ≤10 mg prednisone (or equivalent) per day for at least 2 weeks prior to treatment. Imaging performed within 28 days prior to treatment must document the radiographic stability of CNS lesions and be performed after completion of any CNS-directed therapy.

[0625] ●Concurrent malignancy requiring treatment (present during screening) or history of prior malignancy active within 2 years before randomization (ie, participants with a history of prior malignancy were eligible if treatment was completed at least 2 years before randomization and the patient had no evidence of disease). Participants with a history of prior early-stage basal / squamous cell skin cancer or noninvasive or carcinoma in situ who had received definitive treatment at any time were also eligible.

[0626] ● Participants with conditions requiring systemic treatment with corticosteroids >10 mg daily prednisone equivalents or other immunosuppressive medications, excluding steroid adrenal replacement medications >10 mg daily prednisone equivalents, within 14 days of study treatment administration were permitted in the absence of active autoimmune disease.

[0627] o Treatment with a short course (<5 days) of steroids for up to 7 days prior to initiation of study treatment was permitted.

[0628] 4.6 Study intervention

[0629] The compounds will be administered to participants according to Table 18 below:

[0630] Table 18. Study Interventions for CA116001

[0631]

[0632] Abbreviations: AxMP, adjunctive medicinal product; IMP, investigational medicinal product; PLD, pegylated liposomal doxorubicin.

[0633] Example 5

[0634] 5. Preliminary Results of Phase 1 / 2 Trial (Example 2)

[0635] The dose-evaluation part of the study was designed with two sequential cohorts: 25 mg / m 2 and 33 mg / m 2 Enrollment in two sequential cohorts has been completed. A total of 14 subjects have been enrolled and treated with MORAb-202, with 7 subjects in each cohort. Further studies will be conducted at 25 mg / m 2 Continue Q3W. This regimen has demonstrated acceptable safety and initial antitumor activity. MORAb-202, total antibody, and released eribulin at 25 mg / m 2 The mean PK profiles were comparable to those of the 0.68 mg / kg dose. In most subjects, BSA-based dosing reduced the total amount of drug (mg) compared to the estimated total dose based on BW. Additional testing is planned for biweekly and weekly dosing schedules.

[0636] Selected sequence:

[0637] SEQ ID NO: 1 (MORAb-003 HC CDR1; Kabat): GYGLS

[0638] SEQ ID NO: 2 (MORAb-003 HC CDR2; Kabat): MISSGGSYTYYADSVKG

[0639] SEQ ID NO: 3 (MORAb-003 HC CDR3; Kabat): HGDDPAWFAY

[0640] SEQ ID NO: 4 (MORAb-003 LC CDR1; Kabat): SVSSSISSNNLH

[0641] SEQ ID NO: 5 (MORAb-003 LC CDR2: Kabat): GTSNLAS

[0642] SEQ ID NO: 6 (MORAb-003 LC CDR3; Kabat): QQWSSYPYMYT

[0643] SEQ ID NO: 7 (MORAb-003 HC CDR1; IMGT): GFTFSGYG

[0644] SEQ ID NO: 8 (MORAb-003 HC CDR2; IMGT): ISSGGSYT

[0645] SEQ ID NO: 9 (MORAb-003 HC CDR3; IMGT): ARHGDDPAWFAY

[0646] SEQ ID NO: 10 (MORAb-003 LC CDR1; IMGT): SSISSNN

[0647] SEQ ID NO: 11 (MORAb-003 LC CDR2; IMGT): GTS

[0648] SEQ ID NO: 12 (MORAb-003 LC CDR3; IMGT): QQWSSYPYMYT

[0649] SEQ ID NO: 15 (MORAb-003 heavy chain (HC))

[0650]

[0651]

[0652] SEQ ID NO: 16 (MORAb-003 light chain (LC))

[0653]

[0654] SEQ ID NO: 33 (MORAb-003 heavy chain full-length preprotein amino acid sequence; leader sequence is underlined)

[0655]

[0656] SEQ ID NO: 34 (MORAb-003 light chain full-length preprotein amino acid sequence (leader sequence is underlined))

[0657]

[0658]

[0659] SEQ ID NO: 35(MORAb-003 HC nt)

[0660]

[0661]

[0662] SEQ ID NO: 36 (MORAb-003 LC nt)

[0663]

[0664] SEQ ID NO: 37 (human FRA)

[0665]

[0666] SEQ ID NO: 38 (human FRA nucleotide)

[0667]

[0668]

Claims

1. A method for treating a folate receptor alpha (FRA) expressing cancer, the method comprising administering to a subject in need thereof an antibody-drug conjugate having formula (I): Ab-(LD)p(I) in (i) Ab is an internalizing anti-folate receptor alpha antibody or an internalizing antigen-binding fragment thereof comprising: three heavy chain complementary determining regions (HCDRs) comprising the amino acid sequences of SEQ ID NO: 1 (HCDR1), SEQ ID NO: 2 (HCDR2), and SEQ ID NO: 3 (HCDR3); and three light chain complementary determining regions (LCDRs) comprising the amino acid sequences of SEQ ID NO: 4 (LCDR1), SEQ ID NO: 5 (LCDR2), and SEQ ID NO: 6 (LCDR3), as defined by the Kabat numbering system; or three heavy chain complementary determining regions (HCDRs) comprising the amino acid sequences of SEQ ID NO: 7 (HCDR1), SEQ ID NO: 8 (HCDR2), and SEQ ID NO: 9 (HCDR3); and three light chain complementary determining regions (LCDRs) comprising the amino acid sequences of SEQ ID NO: 10 (LCDR1), SEQ ID NO: 11 (LCDR2), and SEQ ID NO: 12 (LCDR3), as defined by the IMGT numbering system; (ii) D is eribulin; (iii) L is a cleavable linker comprising Mal-(PEG)2-Val-Cit-pAB; and (iv) p is an integer from 1 to 8; and wherein the antibody-drug conjugate is administered at 8 mg to 50 mg of the antibody-drug conjugate / m2 (m 2 ) of the subject's body surface area (BSA) is administered to the subject.

2. A method of reducing the risk of interstitial lung disease (ILD) in a subject being treated for a FRA-expressing cancer, the method comprising administering to the subject an antibody-drug conjugate having formula (I): Ab-(LD)p(I) in (i) Ab is an internalizing anti-folate receptor alpha antibody or an internalizing antigen-binding fragment thereof comprising: three heavy chain complementary determining regions (HCDRs) comprising the amino acid sequences of SEQ ID NO: 1 (HCDR1), SEQ ID NO: 2 (HCDR2), and SEQ ID NO: 3 (HCDR3); and three light chain complementary determining regions (LCDRs) comprising the amino acid sequences of SEQ ID NO: 4 (LCDR1), SEQ ID NO: 5 (LCDR2), and SEQ ID NO: 6 (LCDR3), as defined by the Kabat numbering system; or three heavy chain complementary determining regions (HCDRs) comprising the amino acid sequences of SEQ ID NO: 7 (HCDR1), SEQ ID NO: 8 (HCDR2), and SEQ ID NO: 9 (HCDR3); and three light chain complementary determining regions (LCDRs) comprising the amino acid sequences of SEQ ID NO: 10 (LCDR1), SEQ ID NO: 11 (LCDR2), and SEQ ID NO: 12 (LCDR3), as defined by the IMGT numbering system; (ii) D is eribulin; (iii) L is a cleavable linker comprising Mal-(PEG)2-Val-Cit-pAB; and (iv) p is an integer from 1 to 8; and wherein the antibody-drug conjugate is administered at 8 mg to 50 mg of the antibody-drug conjugate / m2 (m 2 ) of the subject's body surface area (BSA) is administered to the subject.

3. The method of claim 1 or claim 2, wherein the antibody or antigen-binding fragment comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 13 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:

14.

4. The method of any one of claims 1 to 3, wherein the antibody or antigen-binding fragment comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 15 and a light chain comprising the amino acid sequence of SEQ ID NO:

16.

5. The method of any one of claims 1 to 4, wherein the antibody-drug conjugate is MORAb-202.

6. The method of any one of claims 1 to 5, wherein p is 3 to 5.

7. The method of any one of claims 1 to 6, wherein the dose is 8 mg to 44 mg / m 2 The subject's BSA.

8. The method of any one of claims 1 to 7, wherein the dose is 33 mg / m2 The subject's BSA.

9. The method of any one of claims 1 to 7, wherein the dose is 25 mg / m 2 The subject's BSA.

10. The method of any one of claims 1 to 7, wherein the dose is 17 mg / m 2 The subject's BSA.

11. The method of any one of claims 1 to 7, wherein the dose is 15 mg / m 2 The subject's BSA.

12. The method of any one of claims 1 to 7, wherein the dose is 8 mg to 10 mg / m 2 The subject's BSA.

13. The method of claim 8 or claim 9, wherein the method further comprises administering a lower dose / m 2 The subject's BSA was decreased to reduce toxicity.

14. The method of claim 13, wherein the lower dose is 17 mg, 15 mg or 8 mg to 10 mg / m 2 The subject's BSA.

15. The method of any one of claims 1 to 14, wherein the antibody-drug conjugate is administered once every three weeks.

16. The method of any one of claims 1 to 14, wherein the antibody-drug conjugate is administered once every two weeks.

17. The method of any one of claims 1 to 14, wherein the antibody-drug conjugate is administered once a week.

18. The method of any one of claims 1 to 17, wherein the subject has a body weight value in the upper quartile of weight.

19. methods as described in any one of claims 1 to 18, wherein with wherein by dosage based on body weight, for example, by the dosage of 0.5mg to 2mg / kilogram of this experimenter's body weight (BW), for example, by the dosage of 0.9mg to 1.2mg / kilogram of BW, the treatment of this antibody-drug conjugate is compared, the risk of ILD is reduced by at least 5%, at least 10%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19% or at least 20% after using this antibody-drug conjugate.

20. The method of any one of claims 1 to 19, further comprising administering a corticosteroid.

21. The method of claim 20, wherein the corticosteroid is administered prophylactically.

22. The method of claim 20 or claim 21, wherein the corticosteroid is administered simultaneously or sequentially with the antibody-drug conjugate.

23. The method of any one of claims 20 to 22, wherein the corticosteroid is administered before or after administration of the antibody-drug conjugate.

24. The method of any one of claims 20-23, wherein the corticosteroid is dexamethasone.

25. The method of claim 24, wherein the dexamethasone is administered at a dose of 4 mg dexamethasone.

26. The method of claim 24 or claim 25, wherein the dexamethasone is administered at least once a day.

27. The method of claim 26, wherein the dexamethasone is administered twice daily.

28. The method of claim 26 or claim 27, wherein the dexamethasone is administered for at least three days at the start of treatment with the antibody-drug conjugate.

29. The method of any one of claims 24 to 28, wherein the dexamethasone is administered orally.

30. The method of any one of claims 20-23, wherein the corticosteroid is prednisone.

31. The method of claim 30, wherein the prednisone is administered at a dose of 0.5 mg prednisone.

32. The method of claim 30, wherein the prednisone is administered at a dose of 1 mg prednisone.

33. The method of claim 30, wherein the prednisone is administered at a dose of 2 mg prednisone.

34. The method of any one of claims 30 to 33, wherein the prednisone is administered at least once daily.

35. The method of any one of claims 30 to 34, wherein the prednisone is administered for at least 14 days prior to initiation of treatment with the antibody-drug conjugate.

36. The method of any one of claims 30 to 35, wherein the prednisone is administered orally.

37. The method of any one of claims 20-23, wherein the corticosteroid is methylprednisolone.

38. The method of claim 37, wherein the methylprednisolone is administered at a dose of 500-1000 mg prednisone.

39. The method of claim 37 or claim 38, wherein the methylprednisolone is administered at least once daily.

40. The method of any one of claims 37 to 39, wherein the methylprednisolone is administered for at least three days prior to initiation of treatment with the antibody-drug conjugate.

41. The method of any one of claims 37 to 40, wherein the methylprednisolone is administered intravenously.

42. The method of any one of claims 1 to 41, wherein the antibody-drug conjugate is administered intravenously.

43. The method of any one of claims 1 to 42, wherein 33 mg / m 2 dose, and then 25 mg / m 2 of reduced dose.

44. The method of any one of claims 1 to 42, wherein 25 mg / m 2 dose, and then 17 mg / m 2 of reduced dose.

45. The method of any one of claims 1 to 42, wherein 25 mg / m 2 dose, and then 15 mg / m 2 of reduced dose.

46. ​​The method of any one of claims 1 to 42, wherein 15 mg / m 2 dose, and then 8 mg / m 2 Up to 10 mg / m 2 of reduced dose.

47. The method of any one of claims 1 to 46, wherein the FRA-expressing cancer is selected from the group consisting of gastric cancer, ovarian cancer, serous ovarian cancer, serous high-grade ovarian cancer, clear cell ovarian cancer, platinum-resistant ovarian cancer, lung cancer, non-small cell lung cancer, metastatic non-small cell lung cancer, lung carcinoid, colorectal cancer, breast cancer, triple-negative breast cancer, hormone receptor (HR)-positive and HER2-low breast cancer, endometrial cancer, serous endometrial cancer, peritoneal cancer, primary peritoneal cancer, fallopian tube cancer, pancreatic cancer, kidney cancer, renal cell carcinoma, cervical cancer, esophageal cancer, and osteosarcoma.

48. The method of claim 47, wherein the FRA-expressing cancer is ovarian cancer.

49. The method of claim 48, wherein the ovarian cancer is platinum-resistant ovarian cancer (PROC).

50. The method of claim 49, wherein the PROC is serous ovarian carcinoma.

51. The method of claim 50, wherein the serous ovarian cancer is high-grade serous ovarian cancer.

52. The method of claim 47, wherein the FRA-expressing cancer is platinum-resistant primary peritoneal cancer.

53. The method of claim 47, wherein the FRA-expressing cancer is platinum-resistant fallopian tube cancer.

54. The method of claim 47, wherein the FRA-expressing cancer is breast cancer.

55. The method of claim 54, wherein the breast cancer is triple negative breast cancer (TNBC).

56. The method of claim 47, wherein the FRA-expressing cancer is non-small cell lung cancer (NSCLC).

57. The method of claim 47, wherein the FRA-expressing cancer is endometrial carcinoma (EC).

58. The method of any one of claims 47-57, wherein the FRA-expressing cancer is a metastatic cancer.

59. The method of claim 58, wherein the metastatic cancer has no genomic alterations.

60. The method of claim 58, wherein the metastatic cancer has at least one known genomic alteration in at least one of any of the following genes: EGFR, ALK PI3K, AKT, mTOR, RET, MET, BRAF, NTRK, ROS1, and any gene involved in the RAS-MAPK pathway.

61. The method of any one of claims 58-60, wherein the metastatic cancer is non-small cell lung cancer.

62. The method of any one of claims 47-61, wherein the FRA-expressing cancer is a refractory cancer.

63. The method of claim 62, wherein the refractory cancer is unresponsive to targeted therapy.

64. The method of claim 63, wherein the targeted therapy is a targeted therapy against any one of the following genes or variants thereof: EGFR, ALK, BRAF, RET, MET NTRK, and ROS1.

65. The method of claim 62, wherein the refractory cancer is unresponsive to a platinum-based treatment and an immunotherapy-based treatment, wherein the treatments are administered simultaneously or sequentially.

66. The method of claim 65, wherein the platinum-based treatment is platinum-doublet chemotherapy, and wherein the immunotherapy-based treatment is a PD-1 inhibitor or a PD-L1 inhibitor.

67. methods as described in any one in claim 1 to 66, wherein this experimenter does not have following one or more when treatment begins: interstitial lung disease (ILD) and / or pneumonia, ILD and / or pneumonia history, lung-specific disease with clinical significance, pleural effusion, pericardial effusion, previous pneumonectomy, chest radiotherapy history in the past 2 years, autoimmune disorder partner lung involvement, connective tissue disorder partner lung involvement or inflammatory disorder partner lung involvement.

68. The method of any one of claims 1 to 66, wherein the subject does not have one or more of the following: a history of more than three prior therapies for the FRA-expressing cancer, a high neutrophil-to-lymphocyte ratio, or a serum albumin level less than 3 g / dL at the start of treatment.

Citation Information

Patent Citations

  • Delaying pre-term birth

    US20170020529A1

  • Recombinant immunoglobin preparations

    US4816567A

  • Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors

    WO1990005144A1

  • Eribulin-based antibody-drug conjugates and methods of use

    WO2017151979A1